

# What to see when you are looking at confusion: a review of the neuroimaging of acute encephalopathy

Raoul Sutter,<sup>1,2,3,4</sup> Peter W Kaplan<sup>1,2</sup>

► Additional material is published online only. To view please visit the journal online (<http://dx.doi.org/10.1136/jnnp-2014-308216>).

<sup>1</sup>Division of Neurosciences Critical Care, Department of Anesthesiology and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA

<sup>2</sup>Department of Neurology, Johns Hopkins Bayview Medical Center, Baltimore, Maryland, USA

<sup>3</sup>Clinic of Intensive Care Medicine, University Hospital Basel, Basel, Switzerland

<sup>4</sup>Department of Neurology, University Hospital Basel, Basel, Switzerland

## Correspondence to

Dr Raoul Sutter, Department of Neurology and Intensive Care Units, University Hospital Basel, Petersgraben 4, Basel 4031, Switzerland; [Raoul.Sutter@usb.ch](mailto:Raoul.Sutter@usb.ch)

*Institution where the work was performed:* Division of Neurosciences Critical Care, Johns Hopkins University School of Medicine.

Received 31 March 2014

Revised 9 July 2014

Accepted 16 July 2014

Published Online First

4 August 2014

## ABSTRACT

Acute encephalopathy is a clinical conundrum in neurocritical care facing physicians with diagnostic and therapeutic challenges. Encephalopathy arises from several concurrent causes, and delayed diagnosis adds to its grim prognosis. Diagnosis is reached by melding clinical, neurophysiological and biochemical features with various neuroimaging studies. We aimed to compile the pathophysiology of acute encephalopathies in adults, and the contribution of cerebral CT, MRI, MR spectroscopy (MRS), positron emission tomography (PET) and single-photon emission CT (SPECT) to early diagnosis, treatment and prognostication. Reports from 1990 to 2013 were identified. Therefore, reference lists were searched to identify additional publications. Encephalopathy syndromes best studied by neuroimaging emerge from hypoxic-ischaemic injury, sepsis, metabolic derangements, autoimmune diseases, infections and rapidly evolving dementias. Typical and pathognomonic neuroimaging patterns are presented. Cerebral imaging constitutes an important component of diagnosis, management and prognosis of acute encephalopathy. Its respective contribution is dominated by rapid exclusion of acute cerebral lesions and further varies greatly depending on the underlying aetiology and the range of possible differential diagnoses. CT has been well studied, but is largely insensitive, while MRI appears to be the most helpful in the evaluation of encephalopathies. MRS may provide supplementary biochemical information and determines spectral changes in the affected brain tissue. The less frequently used PET and SPECT may delineate areas of high or low metabolic activity or cerebral blood flow. However, publications of MRS, PET and SPECT are limited only providing anecdotal evidence of their usefulness and sensitivity.

## INTRODUCTION

Encephalopathy is a major cause of morbidity and mortality, particularly in the intensive care unit and in postsurgical patients. Acute encephalopathy appears in many forms, producing a constellation of abnormalities with myriad clinical features, dysfunctions reflected in tests on body fluids, abnormalities on EEG and a number of imaging abnormalities. Although individual or even aggregates of tests may not yield a specific diagnosis, they summate to produce a picture that can help the clinician in a directed management plan. Over the past few decades we have witnessed major advances in promising neuroimaging modalities and emerging new acquisition techniques with an increasing

availability. Among neuroimaging techniques, including cerebral CT, brain MRI, single-photon emission CT (SPECT) and positron emission tomography (PET), several have yielded identifiable abnormalities leading to the causes of acute brain dysfunction hence expediting appropriate treatment. In light of the increasing and diverse imaging tools, guidance regarding their diagnostic and prognostic yield in the clinically challenging setting of acute encephalopathy as well as their impact on patient management is evermore important for the clinician.

We therefore aimed to compile the current evidence and to provide a compendium of typical, and in some cases pathognomonic, imaging patterns for the clinician. We review the essential pathophysiology of selected, well-recognised acute encephalopathies in adults, and their respective neuroimaging correlates. Further, we aimed to compile the prognostic value of neuroimaging in these settings.

## DEFINITION OF ENCEPHALOPATHY

There is no international consensus regarding the distinction between encephalopathy, delirium and confusional states. Terms such as ‘delirium’, ‘acute brain syndrome’, ‘acute brain dysfunction’, ‘acute confusional state’, and ‘toxic or metabolic encephalopathy’ are often used synonymously and in an inconsistent manner. The term ‘encephalopathy’ encompasses a wide variety of reversible or permanent, diffuse or multifocal brain dysfunctions caused by myriad physiological derangements ranging from acute structural brain alteration (eg, trauma, ischaemia, haemorrhage, tumour, etc) to non-structural metabolic, toxic and/or infection-related cerebral dysfunction. However, acute encephalopathy, is defined by the American Psychiatric Association as altered consciousness with change in cognition and/or with a perceptual disturbance developing over hours or days and that which was not better accounted for by a pre-existing or evolving chronic dementia.<sup>1</sup>

## IMAGING TECHNIQUES

CT uses computer-processed X-rays to produce tomographic images of the scanned objects. Digital geometry processing generates three-dimensional images based on a large series of two-dimensional radiographies taken around an axis of rotation.

In diffusion-weighted imaging (DWI), a specific MRI sequence, the intensity of each three-dimensional



CrossMark

**To cite:** Sutter R, Kaplan PW. *J Neurol Neurosurg Psychiatry* 2015;**86**:446–459.

image-element (voxel) reflects the estimate of the water diffusion rate in that area. The random motion of water depends on thermal agitation and on its cellular environment. The motion of cellular and intercellular water is hindered primarily by cell membrane boundaries. The diffusion restriction correlates with cellularity of a specific tissue. DWI detects changes of water diffusion that may indicate (early) pathological alterations of membranes and membrane-bound water transporting proteins. The impedance of water molecules diffusion is quantified using the apparent diffusion coefficient (ADC) value. ADC values can be displayed as a parametric map reflecting the degree of water diffusion through different tissues. MR spectroscopy (MRS) allows studies of metabolic changes in brain tissue by using signals from hydrogen protons to determine the relative concentrations of target brain metabolites.

PET is a functional imaging technique using nuclear medicine producing three-dimensional images of physiological and pathological processes in the body. PET detects  $\gamma$ -ray pairs emitted indirectly by administered positron-emitting radionuclides, which are linked to a biologically active molecule. Three-dimensional images based on the detected regional concentration of these radionuclide-linked molecules are constructed automatically.

SPECT is a nuclear medicine tomographic imaging technique using  $\gamma$ -rays. A  $\gamma$ -emitting radionuclide is administered intravenously and emitted  $\gamma$ -rays are detected by  $\gamma$ -cameras. Three-dimensional images are then constructed automatically.

### SEARCH STRATEGY AND SELECTION CRITERIA

We included acute encephalopathies in adolescent and adult patients from metabolic derangements, hypoxic-ischaemic insults, sepsis, autoimmune diseases and rapidly evolving dementias. More chronic or subacute encephalopathies, such as those resulting from multifocal vascular lesions or inborn errors of metabolism were excluded. Further encephalopathies evolving from a large number of exogenous toxins, specific infections other than from herpes simplex virus (HSV), status epilepticus and trauma were excluded, as most of these disorders can indicate a large variety of neuroradiological abnormalities. Studies of functional MRI, diffusion tensor imaging and perfusion-weighted MRI were not included, as in most types of acute encephalopathies studies are lacking.

The Medline search engine was used to identify reports published in any language between 1990 and 2013. The search terms included the names of the different encephalopathic syndromes, or pathological conditions used in the headings throughout the manuscript in combination with “computed tomography”, “magnetic resonance imaging”, “magnetic resonance spectroscopy”, “positron emission tomography”, “single-photon emission computed tomography”, “CT”, “MRI”, “MRS”, “PET”, and “SPECT”. In addition, the reference lists of selected reports were searched to identify additional publications.

Publications are summarised and categorised in the online supplementary tables S1–S3.

### NEUROIMAGING IN ENCEPHALOPATHIC SYNDROMES

#### Hypoxic-ischaemic encephalopathy

*Pathophysiology:* Hypoxic-ischaemic encephalopathy (HIE) usually results from acute circulatory and/or respiratory breakdown and typically affects the cortical and subcortical grey matter structures first. HIE is mainly caused by cardiac arrest, poisoning with carbon monoxide, asphyxiation or drowning. Failure of cerebral oxygenation inhibiting the  $\text{Na}^+\text{-K}^+$  pumps leads to the loss of cellular integrity and release of excitotoxic

glutamate, followed by overstimulation of *N*-methyl-D-aspartate (NMDA) receptors, cellular calcium loss mediated via second messengers and damage of the mitochondrial respiratory chain.<sup>2</sup> Brain reperfusion may cause secondary damage. The severity of injury depends on the duration and degree of circulatory and/or respiratory breakdown, body temperature and serum glucose levels.


*Neuroimaging* (see online supplementary table S1, figure 1A): Cerebral CT is often normal early on, or may reveal mild loss of the grey–white junction in the first hours after cardiorespiratory arrest (CRA). Conversely, brain MRI may show DWI changes within an hour after CRA.<sup>3</sup> In the initial 24 h, there may be symmetric decreases in the thalamus and basal ganglia,<sup>4</sup> loss of differentiation between the grey and white matter, and increases in signal on T2-weighted images.<sup>5</sup> In the late subacute phase of HIE, there are changes in the white and deep grey matter.<sup>6</sup>

Quantitative whole-brain diffusion-weighted MRI on days 2–4 after CRA may provide more accurate prognosis than the neurological examination.<sup>7</sup> In a study of 10 patients, marked DWI, ADC or fluid-attenuated inversion recovery (FLAIR) changes portended poor outcome in 100%.<sup>8</sup> Although early cerebral CT is less sensitive than brain MRI,<sup>9</sup> one study of 53 patients revealed that signs of global cerebral oedema had a false-positive rate of 0% for death.<sup>10</sup> In a study of post-CRA patients treated with hypothermia, quantitative whole-brain diffusion-weighted MRI in this time window improved the sensitivity for predicting poor outcome by 38% while maintaining 100% specificity as compared with the 72 h neurological examination ( $p=0.021$ ).<sup>7</sup> This study was followed by another analysis revealing that DWI 48 h post-CRA with global ischaemia or focal ischaemia with a total lesion volume of  $>20$  mL had a false-positive rate of 0% for a poor outcome (defined as a cerebral performance category of 3–5)<sup>11</sup> while another study showed a false-positive rate of 23% of cortical and/or deep grey nuclei lesions on MRI for a Cerebral Performance Category (CPC) of 3–5.<sup>12</sup> The predictive value of MRI findings is given in table 1. In a small study, MRS distinguished between good and poor outcome with a 100% specificity. The distinction was made with 90% sensitivity after 48 h and became 100% by days 3 and 4.<sup>13</sup> Data from brain PET and SPECT studies are of no additional help. Frequent neuroimaging patterns are summarised in table 2.

#### Sepsis-related encephalopathy

*Pathophysiology:* Although the central nervous system (CNS) may be an ‘immunologically privileged’ organ, separated by the blood–brain barrier from most components of the humoral and cellular immune system, the brain may be exposed to excessive systemic inflammatory responses during sepsis. Cerebral dysfunction reflects the systemic metabolic, inflammatory and haemodynamic disturbances associated with systemic inflammatory response. Septic shock can also cause multifocal necrotising leukoencephalopathy from systemic inflammatory-mediated responses, along with ischaemic brain lesions, haemorrhages and microabscesses.<sup>14</sup>

*Neuroimaging* (figure 1B): In many patients, cerebral CT and MRI are normal, however, in some studies signs of vasogenic oedema can be detected when autoregulation is disturbed.<sup>15</sup> With marked sepsis, there may be multiple lesions of cerebral white matter, and ischaemic strokes located in the centrum semiovale.<sup>16</sup> Signs of ventriculitis with paraventricular ependymal hyperintensities can be present (figure 1B) and periventricular contrast enhancement is often demonstrated best on T1. The patchy white matter lesions are dynamic and change over time.



**Figure 1** MRI of specific acute encephalopathy syndromes. Serial axial fluid-attenuated inversion recovery sequences (on 1.5-T MRI, except A and D which are diffusion-weighted imaging; on 1.5-T MRI). (A) Hypoxic-ischaemic encephalopathy with hyperintense thalami and cortical grey matter; (B) sepsis-related encephalopathy with bilateral patchy hyperintensities in the deep white matter and ependymal hyperintensities along the ventricles (ie, ventriculitis); (C) central pontine myelinolysis (central pontine hyperintensities in the pons (arrows)); and (D) acute hepatic encephalopathy with hyperintensities from a cytotoxic oedema in the globus pallidus (arrows).

There are no sufficient data on MRS, SPECT and PET in humans. Frequent neuroimaging patterns are summarised in [table 2](#).

### Uraemic encephalopathy

**Pathophysiology:** The exact pathophysiology of uraemic encephalopathy is unknown, but reversible ischaemic changes, disorders of cerebral metabolism, and the direct effect of uraemic toxins on intracerebral vascular autoregulation have been implicated.<sup>17</sup>

**Neuroimaging** (see online supplementary table S2): Cerebral CT findings are usually normal, although some reveal attenuation changes in bilateral basal ganglia and internal capsules.<sup>18</sup> Brain MRI has shown T1 hypointensities and T2, FLAIR and

DWI hyperintensities in the same areas, along with changes in cortical zones in some cases.<sup>17</sup> Individual reports in patients without diabetes with uraemia showed extensive supratentorial white matter changes sparing basal ganglia and cortical involvement<sup>19</sup> with diffusion restrictions in some patients. Following haemodialysis, many of these imaging and clinical abnormalities may regress. Nonetheless, in patients with relapsing and remitting uraemia, encephalopathy and concurrent cerebral atrophy progress and the basal ganglia may also be affected resulting in disturbed extrapyramidal movements.<sup>20</sup> MRS reveals a decreased *N*-acetyl-aspartate peak and an elevated lactate peak in the basal ganglia when extrapyramidal movement abnormalities occur.<sup>21</sup> Brain F-18 fluorodeoxyglucose (FDG)-PET in patients with extrapyramidal movement disorders may uncover

**Table 1** Most consistent and pathognomonic neuroimaging patterns in the literature and their predictive value (data from the online supplementary tables S1–S3)

Imaging	Patterns	Predictive value for poor outcome
<b>Hypoxic-ischaemic encephalopathy</b>		
CT	<ul style="list-style-type: none"> <li>▶ Global cerebral oedema</li> <li>▶ Decrease of putaminal, cortical and corticomedullary contrast</li> </ul>	Global oedema false-positive rate 0%. Higher putaminal, cortical and corticomedullary contrast was associated with Cerebral Performance Category (CPC) 4–5
MRI	<ul style="list-style-type: none"> <li>▶ Diffuse signal abnormalities in the cortex and subcortical areas or effacement of the sulci</li> <li>▶ Lower whole-brain and regional median ADC</li> <li>▶ DWI and FLAIR cortical multilobar, or diffuse lesion pattern</li> <li>▶ ADC &lt;650×10<sup>6</sup> mm<sup>2</sup>/s</li> <li>▶ DWI with global ischaemia or focal ischaemia with lesion volume &gt;20 mL</li> <li>▶ T2 and DWI changes in the cerebral cortex and the deep grey matter</li> </ul>	All patients with these findings died  Patients with modified Rankin Scale (mRS) >3 have lower whole-brain and regional ADC  False-positive rate 0% for death, profound cognitive impairment, persistent vegetative state or severe physical impairment
PET	Hypometabolism frontal, parietal including the precuneus, in the posterior cingulate gyrus, and in the occipital areas. Hypermetabolism in the insulas, cerebellum and brainstem	No clear evidence
<b>Sepsis-related encephalopathy</b>		
MRI	<ul style="list-style-type: none"> <li>▶ Vasogenic oedema can be detected when autoregulation is disturbed</li> <li>▶ With marked sepsis, there may be multiple lesions of cerebral white matter, and ischaemic strokes located in the centrum semiovale. The patchy white matter lesions are dynamic and change over time</li> <li>▶ Periventricular contrast enhancement may often be demonstrate best on T1</li> <li>▶ Signs of ventriculitis with paraventricular ependymal hyperintensities can be present</li> </ul>	No clear evidence
<b>Uraemic encephalopathy</b>		
CT	Hypodense basal ganglia and capsules	No clear evidence
MRI	<ul style="list-style-type: none"> <li>▶ T2, FLAIR and DWI hyperintense basal ganglia, capsules and inconsistently in cortical areas</li> <li>▶ Additional involvement of white matter and cerebral peduncles, occipital lobes and thalami</li> <li>▶ Decrease of <i>N</i>-acetyl-aspartate and the presence of lactate on MRS</li> </ul>	No clear evidence
PET	Decreased glucose metabolism in basal ganglia	No clear evidence
<b>Hyperammonaemic encephalopathy</b>		
MRI	<ul style="list-style-type: none"> <li>▶ T2, FLAIR and DWI cortical hyperintensities of the insula and cingulum</li> <li>▶ Increased glutamine and glutamate; low myoinositol and choline on MRS</li> </ul>	No clear evidence
<b>Hepatic encephalopathy</b>		
CT	Usually normal	No clear evidence
MRI	<ul style="list-style-type: none"> <li>▶ T1 hyperintensities in the globus pallidus and, less frequent, in the substantia nigra and the midbrain tegmentum</li> <li>▶ FLAIR and DWI hyperintense thalami, posterior limbs of the internal capsule, periventricular region, dorsal brain stem and diffuse cortical involvement in 1 study of 20 patients</li> <li>▶ <i>Connectivity</i>: decreased in the caudate of the anterior/middle cingulate gyrus; increased in the caudate of the left motor cortex; reduced between the putamen and the anterior cingulate gyrus, right insular lobe, inferior frontal gyrus, left parahippocampal gyrus and the anterior lobe of the right cerebellum; increased between the putamen and right middle temporal gyrus</li> <li>▶ Increased glutamate/glutamine ratio and low myoinositol and choline on MRS</li> <li>▶ Diminished choline and elevated glutamate/glutamine ratio in the parieto-occipital cortex on MRS</li> </ul>	Correlations between the corticostriatal connectivity and neuropsychological performances, but not between the striatal connectivity and globus pallidus signal intensity
SPECT	<ul style="list-style-type: none"> <li>▶ High blood flow in the cerebellum, basal ganglia and cerebral cortex</li> <li>▶ Alteration of striatal D2-receptor binding and dopamine reuptake</li> </ul>	No clear evidence
PET	<ul style="list-style-type: none"> <li>▶ Hypoperfusion of the superior and middle frontal gyri, and inferior parietal lobules</li> <li>▶ Increased peripheral benzodiazepine binding sites prefrontal and striatal in patients with cirrhosis</li> </ul>	No clear evidence
<b>Wernicke's encephalopathy</b>		
CT	Hypodense paraventricular thalamic regions with or without contrast enhancement and, less frequent, hypodense periaqueductal regions, tectum of the midbrain and tegmentum of the pons	No clear evidence
MRI	<ul style="list-style-type: none"> <li>▶ T2 and FLAIR hyperintense periaqueductal and medial thalamic regions. Less-frequent hyperintense mammillary bodies, periaqueductal regions, hypothalamus, tectum and cerebellum</li> <li>▶ Minimised mammillary bodies</li> <li>▶ Contrast-enhanced mammillary bodies is related to alcohol abuse</li> <li>▶ Atrophic mammillary bodies and cerebellar vermis (chronic phase)</li> <li>▶ Thalamic lactate increase and low <i>N</i>-acetyl-aspartate/creatinine on MRS</li> </ul>	No clear evidence
SPECT	Hypoperfusion frontoparietal and in the right basal ganglia	No clear evidence

Continued

**Table 1** Continued

Imaging	Patterns	Predictive value for poor outcome
Hypoglycaemic encephalopathy		
CT	Enhancing, hypodense basal ganglia, cerebral cortex, hippocampus and substantia nigra	No clear evidence
MRI	<ul style="list-style-type: none"> <li>▶ T2 and FLAIR hyperintensities in the caudate, lenticular nuclei, cerebral cortex, substantia nigra, hippocampus and internal capsules</li> <li>▶ In few patients DWI hyperintense white and deep grey matter and splenium of the corpus callosum</li> </ul>	Associated with vegetative state or severe disability in two case series
Hyperglycaemic encephalopathy		
CT	Hyperdense putamen and/or caudate nucleus	No clear evidence
MRI	Unilateral or bilateral T1 hyperintensities in the striatum (mostly putamen)	No clear evidence
SPECT	Hypoperfusion of the basal ganglia	No clear evidence
Hyponatraemic/hypernatraemic encephalopathies (pontine or extrapontine myelinolysis)		
CT	<ul style="list-style-type: none"> <li>▶ Normal in a few patients and hypodense pontine lesions in the others</li> </ul>	No clear evidence
MRI	<ul style="list-style-type: none"> <li>▶ T2, FLAIR and DWI hyperintense lesions of the pons. Less frequent lesions of the thalamus, midbrain, cortical grey matter, hippocampus, caudate, putamen and middle cerebral peduncle</li> <li>▶ T2 hyperintensities may be distributed along the crowns and sides of the cerebral gyri</li> </ul>	No clear evidence
SPECT	Decreased striatal dopamine transporter binding and pontine hyperperfusion during recovery	No clear evidence

ADC, apparent diffusion coefficient; DWI, diffusion-weighted imaging; FLAIR, fluid-attenuated inversion recovery; MRS, MR spectroscopy; PET, positron emission tomography; SPECT, single-photon emission CT.

a decreased glucose metabolism in the basal ganglia.<sup>22</sup> Frequent neuroimaging patterns are summarised in [table 3](#).

### Hyperammonaemia-related encephalopathy

*Pathophysiology:* Hyperammonaemic encephalopathy (HAE) results from the purported toxic effect of ammonia (or other

compounds that co-occur with ammonia), a product of the amino acid metabolism.<sup>23</sup> Ammonia may accumulate when its degradation in the liver is impaired mainly as a result of liver diseases, or by its overproduction in pathological conditions including multiple myeloma, urease-producing bacteria, or drugs (eg, divalproate sodium) that inhibit metabolic pathways.<sup>23</sup> Increased glutamine production during ammonium clearance, changes in osmolarity and death of astrocytes with brain oedema may be the causes of encephalopathy.<sup>23</sup>

*Neuroimaging* (see online supplementary table S2): Cerebral CT may not be particularly helpful. In contrast, two case series of brain MRI findings have revealed bilateral changes in the T2-weighted images and FLAIR sequences of the insula, cingulum, and more diffuse cortical regions using diffusion-weighted sequences.<sup>24</sup> MRS can show increases in glutamate and

**Table 2** Neuroimaging patterns in hypoxic-ischaemic and sepsis-related encephalopathy

Imaging	Patterns
Hypoxic-ischaemic encephalopathy	
CT	<ul style="list-style-type: none"> <li>▶ Global cerebral oedema</li> <li>▶ Decrease of putaminal, cortical and corticomedullary contrast</li> </ul>
MRI	<ul style="list-style-type: none"> <li>▶ Diffuse signal abnormalities in the cortex and subcortical areas or effacement of the sulci</li> <li>▶ Lower whole-brain and regional median ADC</li> <li>▶ DWI and FLAIR cortical multilobar, or diffuse lesion pattern</li> <li>▶ ADC &lt;650×10<sup>6</sup>mm<sup>2</sup>/s</li> <li>▶ DWI with global ischaemia or focal ischaemia with lesion volume &gt;20 mL</li> <li>▶ T2 and DWI changes in the cerebral cortex and the deep grey matter</li> </ul>
PET	Hypometabolism frontal, parietal including the precuneus, in the posterior cingulate gyrus, and in the occipital areas. Hypermetabolism in the insulas, cerebellum and brainstem
Sepsis-related encephalopathy	
MRI	<ul style="list-style-type: none"> <li>▶ Vasogenic oedema can be detected when autoregulation is disturbed</li> <li>▶ With marked sepsis, there may be multiple lesions of cerebral white matter, and ischaemic strokes located in the centrum semiovale. The patchy white matter lesions are dynamic and change over time</li> <li>▶ Periventricular contrast enhancement may often be demonstrated best on T1</li> <li>▶ Signs of ventriculitis with paraventricular ependymal hyperintensities can be present</li> </ul>

ADC, apparent diffusion coefficient; DWI, diffusion-weighted imaging; FLAIR, fluid-attenuated inversion recovery; PET, positron emission tomography.

**Table 3** Neuroimaging patterns in uraemic and hyperammonaemic encephalopathy

Imaging	Patterns
Uraemic encephalopathy	
CT	Hypodense basal ganglia and capsules
MRI	<ul style="list-style-type: none"> <li>▶ T2, FLAIR and DWI hyperintense basal ganglia, capsules and inconsistently in cortical areas</li> <li>▶ Additional involvement of white matter and cerebral peduncles, occipital lobes and thalami</li> <li>▶ Decreased <i>N</i>-acetyl-aspartate and an elevated lactate in the basal ganglia on MRS</li> </ul>
PET	Decreased glucose metabolism in basal ganglia
Hyperammonaemic encephalopathy	
CT	Usually normal
MRI	<ul style="list-style-type: none"> <li>▶ T2, FLAIR and DWI cortical hyperintensities of the insula and cingulum</li> <li>▶ Increased glutamine and glutamate; low myoinositol and choline on MRS</li> </ul>

DWI, diffusion-weighted imaging; FLAIR, fluid-attenuated inversion recovery; MRS, MR spectroscopy; PET, positron emission tomography.

glutamine, decreases in myoinositol and choline possibly representing compensatory mechanisms.<sup>25</sup> In HAE with cirrhosis, PET demonstrates decreased cerebral blood flow with a fall in cerebral metabolic rate for oxygen by 20–40% compared with normal controls.<sup>26</sup> Studies on SPECT in HAE are lacking. Frequent neuroimaging patterns are summarised in table 3.

### Hepatic encephalopathy

*Pathophysiology:* Hepatic encephalopathy (HE) emerges from decompensated cirrhosis or acute hepatic failure. Astrocytic swelling resulting from an accumulation of metabolites is considered a major contributor<sup>25</sup> (see Hyperammonaemia-related encephalopathy section, above).

*Neuroimaging* (see online supplementary table S3, figure 1D): There are few neuroimaging studies on acute HE.<sup>25</sup> Cerebral CT may be normal, or shows non-specific changes in the tectal regions, anterior pituitary and subthalamic nucleus. On MRI, there may be T2 prolongation in the periventricular white matter, thalami, internal capsules, corticospinal tracts and cerebral cortex.<sup>25 27</sup> In acute fulminant hepatic failure, the reversible oedema is astrocytic and mostly affects the globus pallidus, even though the DWI can resemble the (usually fatal) appearance in HIE. Changes in the glutamate/glutamine ratio with decreased myoinositol and choline are seen with MRS<sup>25</sup> and can regress following liver transplantation. There is no evidence for the added diagnostic or prognostic value of MRS, PET and SPECT in HE. Cerebral SPECT may detect an increase in cerebellar, cortical and basal ganglia blood flow,<sup>28</sup> and changes in dopamine D2-receptor binding and reuptake.<sup>29</sup> Some patients with cirrhosis have decreased perfusion in the inferior parietal lobules, and the middle and superior frontal gyri.<sup>30</sup> Many of these changes regress following treatment.

**Table 4** Neuroimaging patterns in hepatic encephalopathy

Imaging	Patterns
Hepatic encephalopathy	
CT	Usually normal
MRI	<ul style="list-style-type: none"> <li>▶ T1 hyperintensities in the globus pallidus and, less frequent, in the substantia nigra and the midbrain tegmentum</li> <li>▶ FLAIR and DWI hyperintense thalami, posterior limbs of the internal capsule, periventricular region, dorsal brain stem and diffuse cortical involvement in 1 study of 20 patients</li> <li>▶ In acute hepatic encephalopathy the widespread grey matter changes on FLAIR and DWI are often reversible, in contrast to anoxic-ischaemic encephalopathy</li> <li>▶ <i>Connectivity:</i> decreased in the caudate of the anterior/middle cingulate gyrus; increased in the caudate of the left motor cortex; reduced between the putamen and the anterior cingulate gyrus, right insular lobe, inferior frontal gyrus, left parahippocampal gyrus and the anterior lobe of the right cerebellum; increased between the putamen and right middle temporal gyrus</li> <li>▶ Increased glutamate/glutamine ratio and low myoinositol and choline on MRS</li> <li>▶ Diminished choline and elevated glutamate/glutamine ratio in the parieto-occipital cortex on MRS</li> </ul>
SPECT	<ul style="list-style-type: none"> <li>▶ High blood flow in the cerebellum, basal ganglia and cerebral cortex</li> <li>▶ Alteration of striatal D2-receptor binding and dopamine reuptake</li> </ul>
PET	<ul style="list-style-type: none"> <li>▶ Hypoperfusion of the superior and middle frontal gyri, and inferior parietal lobules</li> <li>▶ Increased peripheral benzodiazepine binding sites prefrontal and striatal in patients with cirrhosis</li> </ul>

DWI, diffusion-weighted imaging; FLAIR, fluid-attenuated inversion recovery; MRS, MR spectroscopy; PET, positron emission tomography; SPECT, single-photon emission CT.

In a recent study, MRI lesion severity correlated moderately with the clinical outcome but was not significant after Bonferroni correction for multiple comparisons.<sup>27</sup> The predictive value of MRI findings is given in table 1. Frequent neuroimaging patterns are summarised in table 4.

### Hypoglycaemic and hyperglycaemic encephalopathy

*Pathophysiology:* An acute decrease in serum glucose levels usually arises from an excess of hypoglycaemia inducing drugs, exogenous or endogenous insulin. This may release aspartate, an excitatory neurotransmitter, after a decline of the cell membrane ATPase pump activity.

*Neuroimaging* (see online supplementary table S2): Cerebral CT can show enhancing hypodensities in the basal ganglia, cerebral cortex, hippocampus and substantia nigra.<sup>31</sup> Brain MRI is usually more revealing and demonstrates hyperintense T2 signals and diffusion restrictions are believed to represent neuronal death and cytotoxic oedema in the posterior limb of the internal capsules, hippocampi, the basal ganglia and cortical areas.<sup>32</sup> The splenium of the corpus callosum may also show signal changes.<sup>32</sup> Data regarding MRS are lacking and there are only few studies using SPECT, or PET with inconclusive findings.


Nonetheless, case series suggest poor outcome with diffuse and extensive DWI changes in the basal ganglia and deep white matter.<sup>32 33</sup> In two case series of patients with bilateral symmetrical grey and/or white matter lesions, 100% remained severely disabled or in a vegetative state.<sup>32 33</sup> The predictive value of MRI findings is given in table 1. Frequent neuroimaging patterns are summarised in table 5.

**Table 5** Neuroimaging patterns in hypoglycaemic and hyperglycaemic and hyponatraemic and hypernatraemic encephalopathy

Imaging	Patterns
Hypoglycaemic encephalopathy	
CT	Enhancing, hypodense basal ganglia, cerebral cortex, hippocampus and substantia nigra
MRI	<ul style="list-style-type: none"> <li>▶ T2 and FLAIR hyperintensities in the caudate, lenticular nuclei, cerebral cortex, substantia nigra, hippocampus and internal capsules</li> <li>▶ In few patients DWI hyperintense white and deep grey matter and splenium of the corpus callosum</li> </ul>
Hyperglycaemic encephalopathy	
CT	Hyperdense putamen and/or caudate nucleus
MRI	Unilateral or bilateral T1 hyperintensities in the striatum (mostly putamen)
SPECT	Hypoperfusion of the basal ganglia
Hyponatraemic/hypernatraemic encephalopathies (pontine or extrapontine myelinolysis)	
CT	<ul style="list-style-type: none"> <li>▶ Normal in a few patients and hypodense pontine lesions in the others</li> </ul>
MRI	<ul style="list-style-type: none"> <li>▶ T2, FLAIR and DWI hyperintense lesions of the pons. Less frequent lesions of the thalamus, midbrain, cortical grey matter, hippocampus, caudate, putamen and middle cerebral peduncle</li> <li>▶ T2 hyperintensities may be distributed along the crowns and sides of the cerebral gyri</li> </ul>
SPECT	Decreased striatal dopamine transporter binding and pontine hyperperfusion during recovery

DWI, diffusion-weighted imaging; FLAIR, fluid-attenuated inversion recovery; SPECT, single-photon emission CT.

**Figure 2** MRI in Wernicke's encephalopathy. (A) Sagittal diffusion-weighted imaging (on 1.5-T MRI) with typical small corpora mammillaria (corpus albicantia) in Wernicke's encephalopathy (arrow); and (B) axial fluid-attenuated inversion recovery sequences (on 1.5-T MRI) with abnormal hyperintensity of the periaqueductal grey matter (arrows).



### Hyperglycaemic encephalopathy

**Pathophysiology:** Hyperglycaemia frequently occurs in uncontrolled diabetes mellitus. Diffuse brain dysfunction reflects osmotic derangements affecting the subthalamic area, the putamen and the caudate nucleus.<sup>34</sup>

**Neuroimaging** (see online supplementary table S2): In 10 patients, cerebral CT showed hyperdense changes in the putamen, while brain MRI revealed T1-weighted hyperintensities with no T2 signal changes in the basal ganglia.<sup>34</sup> However, these findings are considered inconsistent and in acute hyperosmolar states, neuroimaging (especially MRI) can vary, in the presence of seizures or status epilepticus. Data regarding MRS are lacking. Studies report that brain SPECT shows hypoperfusion in the basal ganglia.<sup>34</sup> When glucose is corrected, imaging

abnormalities regress.<sup>34</sup> SPECT may reveal differences between non-ketotic and ketotic hyperglycaemic encephalopathies. In the former there are often multifocal seizures and extrapyramidal movements that might show corresponding areas of altered metabolism. Frequent neuroimaging patterns are summarised in table 5.

### Hyponatraemic and hypernatraemic encephalopathy (pontine or extrapontine myelinolysis)

**Pathophysiology:** The decreased serum osmolality, primarily from acute hyponatraemia promotes a water shift across the blood-brain barrier into the brain tissue resulting in cerebral oedema and severe neurological dysfunction. The increase of interstitial pressure causes an extracellular fluid shift from the brain tissue into the cerebrospinal fluid. The glial cells and neurons lose solutes, promoting an osmotic movement of water from the intracellular to the extracellular space,<sup>35</sup> subsequent disruption of the blood-brain barrier, and loss of oligodendroglia in the basis pontis. The rapid correction/change of serum sodium levels causes central pontine myelinolysis (CPM)—an effect, which is not entirely understood. This osmotic demyelination can also evolve more diffusely to involve extrapontine regions of the CNS (ie, extrapontine myelinolysis).

**Neuroimaging** (see online supplementary table S2, figure 1C): Cerebral CT reveals evidence of demyelination in ~1/4 of hypodensities without enhancement.<sup>36</sup> Brain MRI delineates more lesions, but normal studies may occur. Abnormalities include T2 hyperintensities in the centre of the pons, the tegmentum and the corticospinal tracts.<sup>5 37</sup> Isolated extrapontine demyelination may occur in ~10% of patients (ie, basal ganglia, thalami, lateral geniculate body, cerebellum and cerebral cortex<sup>5 36 37</sup>), or may occur together with CPM. Lesions can occasionally be seen in the thalamus, putamen, caudate nucleus, midbrain and pons on FLAIR and T2-weighted and T1-weighted imaging—extrapontine lesions seen in >40%.<sup>38</sup> Early examination with diffusion-weighted MRI reveals changes of in water diffusion <1 day after first symptoms.<sup>37</sup> Regional hyperperfusion may be delineated during recovery using SPECT, with decreases in the striatal dopamine transporter in extrapontine myelinolysis.<sup>39</sup>

The severity of demyelination expressed by the volume of MRI signal abnormality, however, may not correspond to the degree of clinical deficit, or return of function, as it is not associated with poor outcome,<sup>36 38</sup> and residual signal changes may persist despite complete clinical recovery. Table 5 summarises frequent neuroimaging patterns.

**Table 6** Neuroimaging patterns in Wernicke's and posterior reversible encephalopathy

Imaging	Patterns
<b>Wernicke's encephalopathy</b>	
CT	Hypodense paraventricular thalamic regions with or without contrast enhancement and, less frequent, hypodense periaqueductal regions, tectum of the midbrain and tegmentum of the pons
MRI	<ul style="list-style-type: none"> <li>▶ T2 and FLAIR hyperintense periaqueductal and medial thalamic regions. Less frequent hyperintense mammillary bodies, periaqueductal regions, hypothalamus, tectum and cerebellum</li> <li>▶ Minimised mammillary bodies</li> <li>▶ Contrast-enhanced mammillary bodies is related to alcohol abuse</li> <li>▶ Atrophic mammillary bodies and cerebellar vermis (chronic phase)</li> <li>▶ Thalamic lactate increase and low <i>N</i>-acetyl-aspartate/creatine on MRS</li> </ul>
SPECT	Hypoperfusion frontoparietal and in the right basal ganglia
<b>Posterior reversible encephalopathy</b>	
CT	Hypodensities in the parieto-occipital subcortical white matter and cerebellum with increased cerebral blood volume, blood flow, and reduced time to peak mainly in the posterior vascular distribution
MRI	<ul style="list-style-type: none"> <li>▶ T2, FLAIR, and DWI hyperintensities in the posterior circulation areas and, less frequent, in the anterior circulation structures. ADC values in areas of abnormal T2 signal are high</li> <li>▶ Contrast enhancement, restrictions on DWI and ADC</li> <li>▶ Decrease in <i>N</i>-acetyl-aspartate in patients with normal MRI or reversible MRI changes and only minimal elevation of choline on MRS</li> </ul>

ADC, apparent diffusion coefficient; DWI, diffusion-weighted imaging; FLAIR, fluid-attenuated inversion recovery; MRS, MR spectroscopy; SPECT, single-photon emission CT.

### Wernicke's encephalopathy

**Pathophysiology:** Wernicke's encephalopathy is caused by a thiamine deficiency in alcohol abuse, malabsorption, poor nutrition, increased metabolism or iatrogenic elimination by haemodialysis. Thiamine deficiency may cause an osmotic imbalance with consequent perineural oedema and neuronal swelling.<sup>40</sup> Periventricular lesions may be explained by a focal high rate of a thiamine-dependent metabolism.<sup>41</sup>


**Neuroimaging** (see online supplementary table S3, [figure 2A,B](#)): Cerebral CT and MRI changes may show hypodensities, or hyperintensities in the midbrain, diencephalon and periventricular areas enhance.<sup>42–43</sup> DWI changes include hyperintensities on T2-weighted, and hypointensities on T1-weighted sequences near the third ventricle, mammillary bodies, the cerebral aqueduct and thalami.<sup>43</sup> Chronically, there may be focal atrophy, especially of the mammillary bodies.<sup>44</sup> MRS reveals a decrease in aspartate and increase in lactate in involved areas.<sup>45</sup> There are no SPECT or PET studies.

Many of the abnormalities regress with treatment, but once there is involvement of the cortex on brain MRI, prognosis is poor in up to 100%.<sup>46</sup> Frequent neuroimaging patterns are summarised in [table 6](#).

### Posterior reversible encephalopathy

**Pathophysiology:** Posterior reversible encephalopathy syndrome (PRES)—a rare and potentially reversible neurotoxic state with a breakdown of the cerebral circulatory autoregulation<sup>47</sup>—is often associated with (pre-)eclampsia and less frequently with other pathological conditions, such as hypertension, sepsis, Guillain-Barré syndrome, autoimmune connective tissue disorders, chemotherapy and organ transplantation. Precursors include vasospasm, vasculitis and serum hyperviscosity.<sup>47</sup> There are different hypotheses regarding the pathogenesis of PRES: (1) capillary vessels secondarily injured by severe arterial hypertension leading to hyperperfusion and cerebral oedema, and (2) hypertension-related reflexive vasoconstriction with secondary brain hypoperfusion and subsequent oedema.<sup>48</sup>

**Neuroimaging** (see online supplementary table S3, [figure 3A](#)): Cerebral CT reveals areas of hypodensity, but may be non-specific. MRI can demonstrate subcortical and cortical oedema in watershed zones, posterior cerebral perfusion areas in parietal and occipital regions, and sometimes also in frontal and temporal watershed zones. Cerebellar changes are less frequent. MRI shows changes that involve several vascular territories in the form of T1 and T2 prolongation,<sup>5</sup> with alterations in the basal ganglia, thalamus, brainstem and *centrum semiovale*.<sup>49</sup> In



**Figure 3** MRI in specific acute encephalopathy syndromes. Serial axial fluid-attenuated inversion recovery sequences (on 1.5-T MRI). (A) Posterior reversible encephalopathy syndrome with widespread confluent subcortical hyperintensities in the posterior circulation; and (B) acute disseminated encephalomyelitis with subcortical hyperintensities in the right frontal lobe (3 images on the right), in the brain stem and in the cerebellar peduncles (3 images on the left); and (C) Creutzfeldt-Jakob disease (arrows mark hyperintense areas of the cortex—the 'cortical ribbon sign' (right arrow)—, putamen and caudate head isointense with the cortical grey (left arrows)).

76 patients with suspected PRES, MRI showed intraparenchymal haemorrhages in only 17%.<sup>49</sup> MRS reveals decreased N-acetyl-aspartate/choline and N-acetyl-aspartate/creatinine ratios outside the areas of oedema.<sup>50</sup> Vasoconstriction may appear on cerebral CT, MR angiography or SPECT.

Neuroimaging changes may regress during days to weeks. The extent of MRI abnormalities correlates with outcome with T2/DWI scores of non-survivors being significantly higher than those of patients who recovered.<sup>51</sup> The predictive value of MRI findings is given in table 7. Frequent neuroimaging patterns are summarised in table 6.

### Autoimmune-induced encephalopathy

#### Acute disseminated encephalomyelitis and the Marburg variant

*Pathophysiology:* Acute disseminated encephalomyelitis (ADEM) is a non-specific term referring to acute CNS inflammation that is postinfectious or parainfectious, postvaccinal or of unknown origin. Exact mechanisms are not understood. The disseminated inflammation is usually monophasic and neurological symptoms result from involvement of cortical and subcortical structures, as well as the spinal cord. There is growing evidence that supports an autoimmune mechanism, as immunological changes, such as increased serum IgA, circulating immune complexes, and a decrease of T and B lymphocytes are frequently found. The exact mechanisms of the Marburg variant of multiple sclerosis, which subsequently follows an aggressive course of demyelination and leads to death within 1 year, remain unclear.<sup>52</sup> There may be severe myelin and axon destruction with prominent tissue necrosis and macrophage infiltration.

*Neuroimaging (figure 3B):* Cerebral CT and MRI are often normal,<sup>53</sup> but abnormalities can occur with contrast enhancement on T2-weighted images and FLAIR sequences in the acute phase.<sup>53</sup> Most patients have multiple brain lesions in the deep and subcortical white matter characteristic of demyelination, and up to 1/3 have lesions in the brainstem and spinal cord.<sup>53 54</sup> DWI shows variable abnormalities depending on the stage of the disease. In the first week (ie, acute phase) DWI reveals a restricted diffusion, and later (ie, subacute phase) diffusion increases.<sup>55</sup> Small MRS studies showed a reduction of N-acetyl-aspartate in regions corresponding to the areas of high T2 signal intensity in the subacute phase.<sup>55</sup> Haemorrhagic demyelinating lesions are mostly seen in the hyperacute ADEM variants. SPECT and PET have not been studied extensively.

Imaging often improves, although lesions may persist. Radiographically, the lesions of the Marburg variant demonstrate significant mass effect and oedema but the patterns may overlap with findings in ADEM. Hence, the Marburg variant may be best considered the most extreme type of demyelinating diseases and distinguishing it from other fulminant variants, such as ADEM may be difficult.<sup>52</sup> Frequent neuroimaging patterns of ADEM are summarised in table 8.

#### Autoimmune and paraneoplastic limbic encephalitis

*Pathophysiology:* Paraneoplastic and autoimmune limbic encephalitis (LE) can develop acutely or subacutely and may represent limbic status epilepticus. Most paraneoplastic LE are associated with autoantibodies and cytotoxic T cells that target the onconeural proteins. Among the many different types of autoimmune and paraneoplastic LE, we focus on NMDA receptor antibody-induced LE and Hashimoto's encephalopathy in the following section.

Anti-NMDA receptor antibody-induced LE is mostly associated with prolonged encephalopathy, with progressive movement disorders, seizures, changes of behaviour, rapid dementia

and confusional states.<sup>56</sup> Hashimoto's encephalopathy or steroid-responsive encephalitis with autoimmune thyroiditis (SREAT)—another specific type of LE—can be associated with Hashimoto's thyroiditis. Some believe that the association is spurious. SREAT is characterised by confusion, psychosis, memory loss, gait problems and subacute or chronic encephalopathy with cognitive decline and even coma. Neuropathological examinations show perivascular inflammatory infiltration,<sup>57</sup> however, the exact mechanisms remain unclear.

*Neuroimaging:* In paraneoplastic LE, cerebral CT is often normal, while the MRI is more sensitive, with contrast enhancing mesial temporal T2 and FLAIR hyperintensities in >50%. Subcortical regions, the cerebellum or brainstem may be involved.<sup>58</sup> A diagnosis is made in almost 80% of patients based on clinical features, presence of paraneoplastic antibodies and the MRI patterns aforementioned. MRI can be used to rule out other aetiologies.<sup>59</sup> PET may reveal increased metabolism mesial temporal.<sup>60</sup>

In NMDA receptor-mediated LE, FLAIR and T2 hyperintensity signal changes typically involve temporal regions, and sometimes extratemporal areas. MRI is used to exclude other causes of acute encephalopathy.

In SREAT, MRI abnormalities are rare (in about 1/3 of patients).<sup>61</sup> However, white matter changes can occur and are atypical, or can resemble ADEM (aforementioned).<sup>62</sup> Other reports include hippocampal and multifocal hyperintensities on T2, FLAIR and DWI with corresponding hypointensities on T1-weighted sequences.<sup>63</sup> MRS reveals decreased N-acetyl-aspartate, myoinositol peaks, elevations in lipid, lactate, glutamate/glutamine and choline peaks. Some cases show regression of these pathological signals after high doses of corticosteroids.<sup>64</sup> On SPECT, decreased tracer uptake in the right striatum<sup>65</sup> and global hypoperfusion of the whole cerebral cortex are reported.<sup>66</sup> Outcome is mostly favourable. Frequent neuroimaging patterns are summarised in table 8. Data from other rarer autoimmune LE are not presented.

#### Herpes simplex encephalitis

*Pathophysiology:* In immunocompetent adults, more than 90% of HSV encephalitis (HSVE) cases are caused by HSV type 1.<sup>67</sup> Whether HSVE is due to primary infection or viral reactivation is uncertain. The pathomechanism of HSV entry into the brain is still undetermined and could be due to viral genome reactivation in the natural reservoir in the trigeminal ganglion with axonal spread via the trigeminal nerve into the CNS, in situ reactivation of the latent virus from CNS tissue, or primary infection of the CNS. Pathways for entry of HSV into the brain include both the olfactory and the trigeminal nerves. Although HSVE is not considered a disorder of the immunocompromised, cases are described in the context of bone marrow transplantation, HIV infection, and in association with an impaired cellular interferon  $\alpha/\beta$  and  $\lambda$  antiviral responses.<sup>68</sup>

*Neuroimaging:* Cerebral CT is usually normal within the first week but can characteristically show reduced attenuation in the temporal lobes later in the course. CT has therefore been substituted by MRI, which is more sensitive, showing FLAIR, T2 and DWI hyperintensities in the medial temporal lobes, the orbital surface of the frontal lobes, the insular cortex, the angular gyrus and in the insulas early in the course in >90% of patients.<sup>69</sup> Abnormal areas may show enhancement with gadolinium. Midline shift may be present with large cerebral oedema. Rarely, brain MRI can be normal.<sup>70</sup> Differences between imaging appearance of LE and herpes simplex encephalitis are

**Table 7** Most consistent and pathognomonic neuroimaging patterns in the literature and their predictive value (data from the online supplementary tables S1–S3)

Imaging	Patterns	Predictive value for poor outcome
<b>Posterior reversible encephalopathy</b>		
CT	Hypodensities in the parieto-occipital subcortical white matter and cerebellum with increased cerebral blood volume, blood flow, and reduced time to peak mainly in the posterior vascular distribution	No clear evidence
MRI	<ul style="list-style-type: none"> <li>▶ T2, FLAIR and DWI hyperintensities in the posterior circulation areas and, less frequent, in the anterior circulation structures. ADC values in areas of abnormal T2 signal are high</li> <li>▶ Contrast enhancement, restrictions on DWI and ADC</li> <li>▶ Decrease in <i>N</i>-acetyl-aspartate on MRS in patients with normal MRI or reversible MRI changes and only minimal elevation of choline</li> </ul>	More extensive T2 signal abnormalities were seen with poor outcome
<b>Acute disseminated encephalomyelitis</b>		
CT	Usually normal	No clear evidence
MRI	<ul style="list-style-type: none"> <li>▶ T2 and FLAIR with multiple brain lesions in the deep and subcortical white matter and in 1/3 in the brainstem and spinal cord characteristic of demyelination with contrast enhancement</li> <li>▶ In the first week (acute phase) DWI with restricted diffusion, and later (subacute phase) with increased diffusion</li> <li>▶ Decreased <i>N</i>-acetyl-aspartate in regions with T2 hyperintensities in the subacute phase on MRS</li> </ul>	No clear evidence
<b>Paraneoplastic limbic encephalitis</b>		
CT	Usually normal	No clear evidence
MRI	<ul style="list-style-type: none"> <li>▶ T2 and FLAIR hyperintensities with mesial temporal contrast enhancement in &gt;50% and/or atrophy</li> <li>▶ Subcortical regions, the cerebellum or brainstem may be involved</li> </ul>	No clear evidence
PET	PET may reveal increased metabolism mesial temporal	No clear evidence
<b>Autoimmune limbic encephalitis</b>		
CT	Usually normal	No clear evidence
MRI	<ul style="list-style-type: none"> <li>▶ In NMDAR-antibody-mediated limbic encephalitis, MRI is mostly (&gt;50%) normal but can show T2 and FLAIR hyperintensities temporal and rarely extratemporal. MRI is used to exclude other causes of encephalopathy</li> <li>▶ In SREAT, T2 and FLAIR can rarely resemble acute demyelinating encephalomyelitis or show hippocampal or multifocal hyperintensities</li> <li>▶ In SREAT, MRS shows decreased <i>N</i>-acetyl-aspartate, myoinositol peaks, elevations in lipid, lactate, glutamate/glutamine and choline peaks support inflammation</li> </ul>	No clear evidence
SPECT	<ul style="list-style-type: none"> <li>▶ In NMDAR-antibody-mediated limbic encephalitis, abnormal multifocal cerebral blood flow</li> <li>▶ In SREAT, decreased tracer uptake in the striatum and global cortical hypoperfusion</li> </ul>	No clear evidence
<b>Herpes simplex encephalitis</b>		
CT	Usually normal, but can characteristically show reduced attenuation in the temporal lobes after the first week of the disease	Lesions on CT are predictive of prolonged course of disease
MRI	<ul style="list-style-type: none"> <li>▶ T2, FLAIR and DWI hyperintensities in the medial temporal lobes, the orbital surface of the frontal lobes, the insular cortex, the angular gyrus and in the insulas early in the course</li> <li>▶ Abnormal areas may show enhancement with gadolinium</li> <li>▶ Midline shift may be present with large cerebral oedema</li> </ul>	The extent of brain involvement is an independent risk factor for poor prognosis
SPECT	Increased tracer accumulation which reflects hyperperfusion possibly earlier than pathological signals appear on MRI	No clear evidence
<b>Susac's syndrome</b>		
CT	Does not reveal any of the specific structural abnormalities, but can demonstrate foci of subtle low attenuation in the corpus callosum	No clear evidence
MRI	<ul style="list-style-type: none"> <li>▶ T2 and FLAIR hyperintensities in the corpus callosum, which is always involved</li> <li>▶ Any part of the corpus callosum can be involved, but predominately the central fibres are showing microinfarcts that are typically small but may sometimes be large</li> <li>▶ Foci in the corpus callosum may enhance following gadolinium administration and there can be restricted diffusion with corresponding low-signal intensity on the ADC map</li> <li>▶ Spinal cord involvement is rare but exists</li> <li>▶ Subsequently, central callosal holes arise</li> </ul>	No clear evidence
PET	Marked hypometabolism in the frontal, parietal and temporal lobes—an unspecific pattern that can be mistaken as ADEM	No clear evidence
<b>Creutzfeldt-Jakob disease</b>		
CT	Non-specific generalised cortical and subcortical atrophy in the later phases of disease	No clear evidence

Continued

Table 7 Continued

Imaging	Patterns	Predictive value for poor outcome
MRI	<ul style="list-style-type: none"> <li>▶ T2 and FLAIR hyperintensities in the cerebral cortex and lesions in the putamen and caudate head isointense to cortex and lesions in the putamen and caudate head isointense to cortical grey</li> <li>▶ Less frequently, hyperintensity can be detected in the globus pallidus, thalamus, the deep white matter, and the cerebral and cerebellar cortex. Laminar lesions may be observed in the cerebral cortex and cerebellum</li> <li>▶ DWI is most sensitive in early stages uncovering the altered diffusion in the regions aforementioned</li> <li>▶ In vCJD symmetrical hyperintensities of the pulvinar thalami (relative to the cortex and especially the anterior part of the putamen) are characteristic and known as the 'pulvinar sign'</li> <li>▶ Decreased <i>N</i>-acetyl-aspartate and slightly increased levels of myoinositol in the striatum and the insular cortex on MRS</li> </ul>	Patients with cortical plus basal ganglia hyperintensity have shorter interval from symptom onset to akinetic mutism than those with isolated cortical ribbon hyperintensity
PET	Hypometabolism in the cerebral cortex and the basal ganglia	No clear evidence
SPECT	Hypoperfusion in the cerebral cortex	No clear evidence

ADC, apparent diffusion coefficient; ADEM, acute disseminated encephalomyelitis; DWI, diffusion-weighted imaging; FLAIR, fluid-attenuated inversion recovery; MRS, MR spectroscopy; NMDAR, *N*-methyl-D-aspartate receptor; PET, positron emission tomography; SPECT, single-photon emission CT; SREAT, steroid-responsive encephalitis with autoimmune thyroiditis; vCJD, variant Creutzfeldt-Jakob disease.

summarised in table 7. Studies of MRS, SPECT and PET are lacking. Case series report an increased tracer accumulation in SPECT, which does not reflect blood-brain barrier disruption or

inflammatory oedema, but rather hyperperfusion possibly earlier than pathological signals appear on MRI.<sup>71</sup>

While small investigations regarding the predictive value of cerebral CT showed that lesions on CT are predictive of prolonged course of the disease,<sup>72-74</sup> a study of 106 patients with HSVE revealed that the extent of brain involvement on MRI at admission is an independent risk factor for poor prognosis.<sup>69</sup> Frequent neuroimaging patterns are summarised in table 9.

Table 8 Frequent neuroimaging patterns in autoimmune-induced encephalopathy

Imaging	Patterns
Acute disseminated encephalomyelitis	
CT	Usually normal
MRI	<ul style="list-style-type: none"> <li>▶ T2 and FLAIR hyperintensities in multiple brain regions, mostly in the deep and subcortical white matter, and up to 1/3 have hyperintense lesions in the spinal cord especially acutely, with contrast enhancement</li> <li>▶ DWI shows variable abnormalities depending on the stage of the disease. In the first week (ie, acute phase) DWI reveals a restricted diffusion, and later (ie, subacute phase) diffusion increases</li> <li>▶ Brainstem and spinal cord abnormalities on MRI are common</li> <li>▶ Haemorrhagic demyelinating lesions are mostly seen in the hyperacute ADEM variants</li> <li>▶ Reduction of <i>N</i>-acetyl-aspartate in regions corresponding to the areas of high T2 signal intensity in the subacute phase in MRS</li> </ul>
Autoimmune and paraneoplastic limbic encephalitis	
CT	Usually normal
MRI	<ul style="list-style-type: none"> <li>▶ Contrast enhancing mesial temporal T2 and FLAIR hyperintensities in &gt;50%</li> <li>▶ Subcortical regions, the cerebellum or brainstem may be involved</li> <li>▶ In NMDAR-antibody-mediated limbic encephalitis MRI is often normal. Sometimes, however, FLAIR and T2 hyperintensity signal changes typically involve temporal regions, and sometimes extratemporal areas</li> <li>▶ In SREAT, white matter changes are atypical, however, MRI findings can resemble acute demyelinating encephalomyelitis. Hippocampal hyperintensities and multifocal hyperintensities on T2, FLAIR and DWI with corresponding hypointensities on T1 may appear</li> <li>▶ In SREAT, decreased <i>N</i>-acetyl-aspartate, myoinositol peaks, elevations in lipid, lactate, glutamate/glutamine and choline peaks on MRS support inflammation</li> <li>▶ Some cases show imaging regression after high doses of corticosteroids</li> </ul>
SPECT	In SREAT, decreased tracer uptake in the striatum and global hypoperfusion of the whole cerebral cortex

ADEM, acute disseminated encephalomyelitis; DWI, diffusion-weighted imaging; FLAIR, fluid-attenuated inversion recovery; MRS, MR spectroscopy; NMDAR, *N*-methyl-D-aspartate receptor; SPECT, single-photon emission CT; SREAT, steroid-responsive encephalitis with autoimmune thyroiditis.

### Susac's syndrome-related encephalopathy

*Pathophysiology:* Susac's syndrome is a rare disease that is characterised by the clinical triad of encephalopathy, branch retinal artery occlusion, and sensorineural hearing loss.<sup>75</sup> The pathogenesis of Susac's syndrome remains unclear. Different mechanistic hypothesis have been implicated, such as immune mechanisms, vasospastic phenomena, coagulopathy and viral infection. However, these hypotheses remain unproven. The diagnosis is mainly based on brain MRI, retinal fluorescein angiography and audiometry.

*Neuroimaging:* Cerebral CT mostly does not reveal any of the specific structural abnormalities, but can demonstrate foci of subtle low attenuation in the corpus callosum.<sup>76</sup> T2 and FLAIR sequences of brain MRI are very sensitive detecting signal changes in the corpus callosum, which is always involved. Any part of the corpus callosum can be affected, but predominately the central fibres show microinfarcts that are typically small.<sup>76</sup> Foci in the corpus callosum often mildly enhance following gadolinium administration and

Table 9 Neuroimaging patterns in herpes simplex encephalitis

Imaging	Patterns
Herpes simplex encephalitis	
CT	Usually normal, but can characteristically show reduced attenuation in the temporal lobes after the first week of the disease
MRI	<ul style="list-style-type: none"> <li>▶ T2, FLAIR and DWI hyperintensities in the medial temporal lobes, the orbital surface of the frontal lobes, the insular cortex, the angular gyrus, and in the insulas early in the course</li> <li>▶ Abnormal areas may show enhancement with gadolinium</li> <li>▶ Midline shift may be present with large cerebral oedema</li> </ul>
SPECT	Increased tracer accumulation which reflects hyperperfusion possibly earlier than pathological signals appear on MRI

DWI, diffusion-weighted imaging; FLAIR, fluid-attenuated inversion recovery; SPECT, single-photon emission CT.

**Table 10** Neuroimaging patterns in encephalopathy caused by Susac's syndrome

Imaging	Patterns
Susac's syndrome-related encephalopathy	
CT	Does not reveal any of the specific structural abnormalities, but can demonstrate foci of subtle low attenuation in the corpus callosum
MRI	<ul style="list-style-type: none"> <li>▶ T2 and FLAIR hyperintensities in the corpus callosum, which is always involved</li> <li>▶ Any part of the corpus callosum can be involved, but predominately the central fibres are showing microinfarcts that are typically small but may sometimes be large</li> <li>▶ Foci in the corpus callosum may enhance following gadolinium administration and there can be restricted diffusion with corresponding low-signal intensity on the ADC map</li> <li>▶ Spinal cord involvement is rare but exists</li> <li>▶ Subsequently, central callosal holes arise</li> </ul>
PET	Marked hypometabolism in the frontal, parietal and temporal lobes—an unspecific pattern that can be mistaken as ADEM

ADC, apparent diffusion coefficient; ADEM, acute disseminated encephalomyelitis; FLAIR, fluid-attenuated inversion recovery; PET, positron emission tomography.

there can be restricted diffusion with corresponding low-signal intensity on the ADC map.<sup>76</sup> These are followed by central callosal holes which may be pathognomonic.<sup>77</sup> Aside from these typical findings, any part of the brain can be affected, but the white matter is most frequently involved.<sup>78</sup> Few articles of MRS report no further useful information in this context and studies of SPECT are lacking. Case reports of brain FDG-PET show marked widespread hypometabolism in the frontal, parietal and temporal lobes—an unspecific pattern that can be mistaken as ADEM.<sup>79</sup> Frequent neuroimaging patterns are summarised in [table 10](#).

### Creutzfeldt-Jakob disease

**Pathophysiology:** Prion diseases are transmissible neurodegenerative diseases with long incubation periods. Once clinical symptoms appear, the fatal course of the disease is inexorable. From the currently known human prion diseases kuru,

**Table 11** Neuroimaging patterns in encephalopathy caused by Creutzfeldt-Jakob disease

Imaging	Patterns
Creutzfeldt-Jakob disease-related encephalopathy	
CT	Non-specific generalised cortical and subcortical atrophy in the later phases of disease
MRI	<ul style="list-style-type: none"> <li>▶ T2 and FLAIR hyperintensities in the cerebral cortex and lesions in the putamen and caudate head isointense to cortex lesions in the putamen and caudate head isointense to cortical grey</li> <li>▶ Less frequently, hyperintensity can be detected in the globus pallidus, thalamus, the deep white matter, and the cerebral and cerebellar cortex. Laminar lesions may be observed in the cerebral cortex and cerebellum</li> <li>▶ DWI is most sensitive in early stages uncovering the altered diffusion in the regions aforementioned</li> <li>▶ In vCJD symmetrical hyperintensities of the pulvinar thalami (relative to the cortex and especially the anterior part of the putamen) are characteristic and known as the 'pulvinar sign'</li> <li>▶ Decreased <i>N</i>-acetyl-aspartate and slightly increased levels of myoinositol in the striatum and the insular cortex on MRS</li> </ul>
SPECT	Hypoperfusion in the cerebral cortex
PET	Hypometabolism in the cerebral cortex and the basal ganglia

DWI, diffusion-weighted imaging; FLAIR, fluid-attenuated inversion recovery; MRS, MR spectroscopy; PET, positron emission tomography; SPECT, single-photon emission CT; vCJD, variant Creutzfeldt-Jakob disease.

Creutzfeldt-Jakob disease (CJD), variant CJD (vCJD), Gerstmann-Sträussler-Scheinker syndrome, and fatal familial insomnia, CJD is the most prevalent (>90% of the prion diseases).<sup>80</sup> In spongiform encephalopathies, prions can induce a pathological refolding of native proteins—a self-sustaining process leading to insoluble proteins that disrupt neuronal function and cause cell death. Neuronal loss, glial proliferation, absence of inflammation and small vacuoles within the neuropil, are common pathological characteristics.

**Neuroimaging (figure 3C):** While cerebral CT shows non-specific generalised cortical and subcortical atrophy in the later phases of disease,<sup>81</sup> MRI is more helpful. Typically, the putamen and caudate head are isointense to cortical grey on T2 and FLAIR.<sup>82</sup> Less frequently, hyperintensity can be detected in the globus pallidus, thalamus, the deep white matter, and the cerebral and cerebellar cortex. Laminar lesions may be observed in the cerebral cortex and cerebellum. Proton density and DWI are more sensitive, especially for cortical lesions. DWI is most sensitive in early stages of CJD and can uncover brain abnormalities before the onset of clinical symptoms, such as myoclonus.<sup>83</sup> One study of MRI in 90 patients demonstrated that the combination of FLAIR and DWI hyperintensities and restricted diffusion could reliably differentiate between CJD and other rapidly progressive dementia with a high sensitivity (94%) and specificity (100%).<sup>84</sup> However, a study of more than 1000 patients with pathologically confirmed CJD found that MRI interpretation had a sensitivity of 46% when obtained at least 6 months after CJD onset, requiring some caution when interpreting MRI.<sup>85</sup> MRI abnormalities may vary with the clinical syndrome and molecular subtypes. In late or terminal stages of CJD prominent generalised cortical and subcortical atrophy is seen. In vCJD symmetrical hyperintensities of the pulvinar thalami (relative to the cortex and especially the anterior part of the putamen) are characteristic and known as the 'putaminal sign'.<sup>86</sup> Descriptions of abnormal MRS, PET and SPECT are limited to single case reports of patients with sporadic CJD and have not been further evaluated.

Patients with cortical plus basal ganglia hyperintensity have shorter interval from symptom onset to akinetic mutism than those with isolated cortical ribbon hyperintensity.<sup>87</sup> Frequent neuroimaging patterns are summarised in [table 11](#).

### Toxic encephalopathies

Another important group of acute encephalopathies, the toxic encephalopathies resulting from exogenous substances, may appear with typical or unspecific imaging patterns. Rather typical imaging patterns, as putaminal lesions may be found on MRI in methanol intoxication<sup>88 89</sup> and a diffuse swelling and bipallidal haemorrhages in ethylene glycol poisoning.<sup>90</sup> A comprehensive summary of all toxic encephalopathies is beyond the scope of this review.

### SUMMARY

Cerebral imaging constitutes an important component of diagnosis, management and prognosis of acute encephalopathy. Its respective contribution is dominated by rapid exclusion of acute cerebral lesions and further varies greatly depending on the underlying aetiology and the range of possible differential diagnoses. For these disorders, cerebral CT has been well studied, but is largely insensitive, while brain MRI and especially DWI have been widely reported and appear to be the most helpful in the evaluation of acute encephalopathies. MRS may provide supplementary biochemical information and determines spectral changes in the affected brain tissue. PET and SPECT have their

use in delineating areas of high or low metabolic activity or cerebral blood flow (eg, with LE or vasospasm). However, in most of the compiled types of acute encephalopathy, publications of MRS, PET and SPECT are limited to case reports and small case series only providing anecdotal evidence of their usefulness and sensitivity, not to mention that the observations are often heavily technique dependent. Most consistent and pathognomonic neuroimaging patterns and their prognostic are compiled in tables 1 and 7. To date, the prognostic value of specific imaging patterns has been quantified especially for MRI in patients with HIE, hypoglycaemic encephalopathy and PRES while in other encephalopathies larger studies are needed to provide such critical information. Many of the imaging changes are non-specific, and the clinician must judiciously use cerebral imaging to supplement clinical impressions, relevant blood, urine or antibody tests, EEG and occasionally body PET. Findings can then be used to guide treatment and occasionally point to outcome in these morbid conditions.

**Contributors** RS and PWK conceived and planned the work, acquired, analysed and interpreted the data, and wrote a first draft of the manuscript. Both the authors approved the final submitted version.

**Competing interests** RS is supported by the Research Funds of the University of Basel, the Scientific Society Basel, and the Gottfried Julia Bangerter-Rhyner Foundation. PWK reports grants from Qatar National Research Foundation, personal fees from Royalties Wiley, Demos for books on epilepsy and EEG; honoraria for international congresses and grand rounds Europe and North America; travel to give lectures Europe and North America; consulting fee for EEG reading Esai Pharma; Expert testimony on qEEG in the courtroom, non-financial support from non-paid board member ACNS and ABCN, outside the submitted work.

**Provenance and peer review** Not commissioned; externally peer reviewed.

## REFERENCES

- American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-IV. Task Force on DSM-IV, editor. American Psychiatric Publication, 2000.
- Choi DW. Excitotoxic cell death. *J Neurobiol* 1992;23:1261–76.
- Kaplan PW, Rossetti AO. EEG patterns and imaging correlations in encephalopathy: encephalopathy part II. *J Clin Neurophysiol* 2011;28:233–51.
- Huang BY, Castillo M. Hypoxic-ischemic brain injury: imaging findings from birth to adulthood. *Radiographics* 2008;28:417–39; quiz 617.
- Bathla G, Hegde AN. MRI and CT appearances in metabolic encephalopathies due to systemic diseases in adults. *Clin Radiol* 2013;68:545–54.
- Arbelaez A, Castillo M, Mukherji SK. Diffusion-weighted MR imaging of global cerebral anoxia. *AJNR Am J Neuroradiol* 1999;20:999–1007.
- Wijman CA, Mlynash M, Caulfield AF, et al. Prognostic value of brain diffusion-weighted imaging after cardiac arrest. *Ann Neurol* 2009;65:394–402.
- Wijdicks EF, Campeau NG, Miller GM. MR imaging in comatose survivors of cardiac resuscitation. *AJNR Am J Neuroradiol* 2001;22:1561–5.
- Stevens RD, Sutter R. Prognosis in severe brain injury. *Crit Care Med* 2013;41:1104–23.
- Fugate JE, Wijdicks EF, Mandrekar J, et al. Predictors of neurologic outcome in hypothermia after cardiac arrest. *Ann Neurol* 2010;68:907–14.
- Choi SP, Park KN, Park HK, et al. Diffusion-weighted magnetic resonance imaging for predicting the clinical outcome of comatose survivors after cardiac arrest: a cohort study. *Crit Care* 2010;14:R17.
- Cronberg T, Rundgren M, Westhall E, et al. Neuron-specific enolase correlates with other prognostic markers after cardiac arrest. *Neurology* 2011;77:623–30.
- Kreis R, Arcinue E, Ernst T, et al. Hypoxic encephalopathy after near-drowning studied by quantitative 1H-magnetic resonance spectroscopy. *J Clin Invest* 1996;97:1142–54.
- Sharshar T, Annane D, de la Grandmaison GL, et al. The neuropathology of septic shock. *Brain Pathol* 2004;14:21–33.
- Piazza O, Cotena S, De Robertis E, et al. Sepsis associated encephalopathy studied by MRI and cerebral spinal fluid S100B measurement. *Neurochem Res* 2009;34:1289–92.
- Sharshar T, Carlier R, Bernard F, et al. Brain lesions in septic shock: a magnetic resonance imaging study. *Intensive Care Med* 2007;33:798–806.
- Park JH, Kim HJ, Kim SM. Acute chorea with bilateral basal ganglia lesions in diabetic uremia. *Can J Neurol Sci* 2007;34:248–50.
- Wang HC, Brown P, Lees AJ. Acute movement disorders with bilateral basal ganglia lesions in uremia. *Mov Disord* 1998;13:952–7.
- Kang E, Jeon SJ, Choi SS. Uremic encephalopathy with atypical magnetic resonance features on diffusion-weighted images. *Korean J Radiol* 2012;13:808–11.
- Sheu YL, Cheng SJ, Chen YM, et al. The syndrome of bilateral basal ganglia lesions in diabetic uremic patients presenting with a relapsing and remitting course: a case report. *Acta Neurol Taiwan* 2007;16:226–30.
- Dicuozzo F, Di Fede R, Salvati A, et al. Acute extrapyramidal disorder with bilateral reversible basal ganglia lesions in a diabetic uremic patient: diffusion-weighted imaging and spectroscopy findings. *J Neurol Sci* 2010;293:119–21.
- Wang HC, Hsu JL, Shen YY. Acute bilateral basal ganglia lesions in patients with diabetic uremia: an FDG-PET study. *Clin Nucl Med* 2004;29:475–8.
- Rimar D, Bitterman H. Hyperammonemic coma: beyond hepatic encephalopathy. *South Med J* 2008;101:467–8.
- Takanashi J, Barkovich AJ, Cheng SF, et al. Brain MR imaging in acute hyperammonemic encephalopathy arising from late-onset ornithine transcarbamylase deficiency. *AJNR Am J Neuroradiol* 2003;24:390–3.
- Rovira A, Alonso J, Cordoba J. MR imaging findings in hepatic encephalopathy. *AJNR Am J Neuroradiol* 2008;29:1612–21.
- Nomiyama K, Tsuji H, Ikeda K, et al. [Positron emission tomography (PET) before and after treatment of hyperammonemia in a patient with decompensated liver cirrhosis]. *Fukuoka Igaku Zasshi* 1991;82:521–7.
- McKinney AM, Lohman BD, Sarikaya B, et al. Acute hepatic encephalopathy: diffusion-weighted and fluid-attenuated inversion recovery findings, and correlation with plasma ammonia level and clinical outcome. *AJNR Am J Neuroradiol* 2010;31:1471–9.
- Kohira I, Matsuo E, Shiro Y, et al. Hepatic encephalopathy with increased cerebral blood flow in SPECT and MRI abnormalities in the basal ganglia. *Jpn J Psychiatry Neurol* 1994;48:33–6.
- Weissenborn K, Berding G, Kostler H. Altered striatal dopamine D2 receptor density and dopamine transport in a patient with hepatic encephalopathy. *Metab Brain Dis* 2000;15:173–8.
- Nakagawa Y, Matsumura K, Iwasa M, et al. Single photon emission computed tomography and statistical parametric mapping analysis in cirrhotic patients with and without minimal hepatic encephalopathy. *Ann Nucl Med* 2004;18:123–9.
- Fujioka M, Okuchi K, Hiramatsu KI, et al. Specific changes in human brain after hypoglycemic injury. *Stroke* 1997;28:584–7.
- Lim CC, Gan R, Chan CL, et al. Severe hypoglycemia associated with an illegal sexual enhancement product adulterated with glibenclamide: MR imaging findings. *Radiology* 2009;250:193–201.
- Ma JH, Kim YJ, Yoo WJ, et al. MR imaging of hypoglycemic encephalopathy: lesion distribution and prognosis prediction by diffusion-weighted imaging. *Neuroradiology* 2009;51:641–9.
- Lai PH, Tien RD, Chang MH, et al. Chorea-ballismus with nonketotic hyperglycemia in primary diabetes mellitus. *AJNR Am J Neuroradiol* 1996;17:1057–64.
- Strange K, Jackson PS. Swelling-activated organic osmolyte efflux: a new role for anion channels. *Kidney Int* 1995;48:994–1003.
- Menger H, Jorg J. Outcome of central pontine and extrapontine myelinolysis (n = 44). *J Neurol* 1999;246:700–5.
- Ruzek KA, Campeau NG, Miller GM. Early diagnosis of central pontine myelinolysis with diffusion-weighted imaging. *AJNR Am J Neuroradiol* 2004;25:210–13.
- Graff-Radford J, Fugate JE, Kaufmann TJ, et al. Clinical and radiologic correlations of central pontine myelinolysis syndrome. *Mayo Clin Proc* 2011;86:1063–7.
- Kim JS, Lee KS, Han SR, et al. Decreased striatal dopamine transporter binding in a patient with extrapontine myelinolysis. *Mov Disord* 2003;18:342–5.
- Zuccoli G, Gallucci M, Capellades J, et al. Wernicke encephalopathy: MR findings at clinical presentation in twenty-six alcoholic and nonalcoholic patients. *AJNR Am J Neuroradiol* 2007;28:1328–31.
- Victor M, Adams RD, Collins GH. The Wernicke-Korsakoff syndrome. A clinical and pathological study of 245 patients, 82 with post-mortem examinations. *Contemp Neurol Ser* 1971;7:1–206.
- Antunez E, Estruch R, Cardenal C, et al. Usefulness of CT and MR imaging in the diagnosis of acute Wernicke's encephalopathy. *AJR Am J Roentgenol* 1998;171:1131–7.
- Gallucci M, Bozzao A, Splendiani A, et al. Wernicke encephalopathy: MR findings in five patients. *AJNR Am J Neuroradiol* 1990;11:887–92.
- Park SH, Kim M, Na DL, et al. Magnetic resonance reflects the pathological evolution of Wernicke encephalopathy. *J Neuroimaging* 2001;11:406–11.
- Murata T, Fujito T, Kimura H, et al. Serial MRI and (1)H-MRS of Wernicke's encephalopathy: report of a case with remarkable cerebellar lesions on MRI. *Psychiatry Res* 2001;108:49–55.
- Fei GQ, Zhong C, Jin L, et al. Clinical characteristics and MR imaging features of nonalcoholic Wernicke encephalopathy. *AJNR Am J Neuroradiol* 2008;29:164–9.
- Hinchev J, Chaves C, Appignani B, et al. A reversible posterior leukoencephalopathy syndrome. *N Engl J Med* 1996;334:494–500.
- Bartynski WS. Posterior reversible encephalopathy syndrome, part 2: controversies surrounding pathophysiology of vasogenic edema. *AJNR Am J Neuroradiol* 2008;29:1043–9.

- 49 McKinney AM, Short J, Truwit CL, *et al.* Posterior reversible encephalopathy syndrome: incidence of atypical regions of involvement and imaging findings. *AJR Am J Roentgenol* 2007;189:904–12.
- 50 Eichler FS, Wang P, Wityk RJ, *et al.* Diffuse metabolic abnormalities in reversible posterior leukoencephalopathy syndrome. *AJNR Am J Neuroradiol* 2002;23:833–7.
- 51 Covarrubias DJ, Luetner PH, Campeau NG. Posterior reversible encephalopathy syndrome: prognostic utility of quantitative diffusion-weighted MR images. *AJNR Am J Neuroradiol* 2002;23:1038–48.
- 52 Rahmlow MR, Kantarci O. Fulminant demyelinating diseases. *Neurohospitalist* 2013;3:81–91.
- 53 Caldemeyer KS, Smith RR, Harris TM, *et al.* MRI in acute disseminated encephalomyelitis. *Neuroradiology* 1994;36:216–20.
- 54 Campi A, Filippi M, Comi G, *et al.* Acute transverse myelopathy: spinal and cranial MR study with clinical follow-up. *AJNR Am J Neuroradiol* 1995;16:115–23.
- 55 Balasubramanya KS, Kovoov JM, Jayakumar PN, *et al.* Diffusion-weighted imaging and proton MR spectroscopy in the characterization of acute disseminated encephalomyelitis. *Neuroradiology* 2007;49:177–83.
- 56 Dalmau J, Gleichman AJ, Hughes EG, *et al.* Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. *Lancet Neurol* 2008;7:1091–8.
- 57 Duffey P, Yee S, Reid IN, *et al.* Hashimoto's encephalopathy: postmortem findings after fatal status epilepticus. *Neurology* 2003;61:1124–6.
- 58 Gultekin SH, Rosenfeld MR, Voltz R, *et al.* Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings and tumour association in 50 patients. *Brain* 2000;123(Pt 7):1481–94.
- 59 Lawn ND, Westmoreland BF, Kiely MJ, *et al.* Clinical, magnetic resonance imaging, and electroencephalographic findings in paraneoplastic limbic encephalitis. *Mayo Clin Proc* 2003;78:1363–8.
- 60 Basu S, Alavi A. Role of FDG-PET in the clinical management of paraneoplastic neurological syndrome: detection of the underlying malignancy and the brain PET-MRI correlates. *Mol Imaging Biol* 2008;10:131–7.
- 61 Yoneda M. [Diagnosis and treatments of Hashimoto's encephalopathy]. *Rinsho Shinkeigaku* 2012;52:1240–2.
- 62 Mahad DJ, Staugaitis S, Ruggieri P, *et al.* Steroid-responsive encephalopathy associated with autoimmune thyroiditis and primary CNS demyelination. *J Neurol Sci* 2005;228:3–5.
- 63 Su TH, Jin EH, He W. Hashimoto encephalopathy: a case report with proton MR spectroscopic findings. *Chin Med J (Engl)* 2011;124:3420–2.
- 64 Zhao W, Li J, Wang J, *et al.* A case of Hashimoto encephalopathy: clinical manifestation, imaging, pathology, treatment, and prognosis. *Neurologist* 2011;17:141–3.
- 65 Hsu CS, Wu YC, Lu MK, *et al.* 99mTc ECD and 99mTc TRODAT-1 SPECT in Hashimoto encephalopathy. *Clin Nucl Med* 2012;37:e86–8.
- 66 Fuertes J, Garcia-Burillo A, Castell-Conesa J, *et al.* Functional neuroimaging in Hashimoto's encephalitis: a physiopathological imaging? *Eur J Nucl Med Mol Imaging* 2009;36:726.
- 67 Aurelius E, Johansson B, Skoldenberg B, *et al.* Encephalitis in immunocompetent patients due to herpes simplex virus type 1 or 2 as determined by type-specific polymerase chain reaction and antibody assays of cerebrospinal fluid. *J Med Virol* 1993;39:179–86.
- 68 Casrouge A, Zhang SY, Eidsencken C, *et al.* Herpes simplex virus encephalitis in human UNC-93B deficiency. *Science* 2006;314:308–12.
- 69 Sili U, Kaya A, Mert A, *et al.* Herpes simplex virus encephalitis: clinical manifestations, diagnosis and outcome in 106 adult patients. *J Clin Virol* 2014;60:112–18.
- 70 Baringer JR. Herpes simplex infections of the nervous system. *Neurol Clin* 2008;26:657–74, viii.
- 71 Hasegawa Y, Morishita M, Ikeda T, *et al.* Early diagnosis of herpes simplex virus encephalitis by single photon emission computed tomography (SPECT) in patients with normal MRI. *Rinsho Shinkeigaku* 1996;36:475–80.
- 72 Riancho J, Delgado-Alvarado M, Sedano MJ, *et al.* Herpes simplex encephalitis: clinical presentation, neurological sequelae and new prognostic factors. Ten years of experience. *Neurol Sci* 2013;34:1879–81.
- 73 Taira N, Kamei S, Morita A, *et al.* Predictors of a prolonged clinical course in adult patients with herpes simplex virus encephalitis. *Intern Med* 2009;48:89–94.
- 74 Mekan SF, Wasay M, Khelaeni B, *et al.* Herpes simplex encephalitis: analysis of 68 cases from a tertiary care hospital in Karachi, Pakistan. *J Pak Med Assoc* 2005;55:146–8.
- 75 Susac JO, Hardman JM, Selhorst JB. Microangiopathy of the brain and retina. *Neurology* 1979;29:313–16.
- 76 Allmendinger AM, Spektor V, Destian S. CT and MR imaging of Susac syndrome in a young male presenting with acute disorientation. *Clin Imaging* 2010;34:138–42.
- 77 Gross M, Eliashar R. Update on Susac's syndrome. *Curr Opin Neurol* 2005;18:311–14.
- 78 White ML, Zhang Y, Smoker WR. Evolution of lesions in Susac syndrome at serial MR imaging with diffusion-weighted imaging and apparent diffusion coefficient values. *AJNR Am J Neuroradiol* 2004;25:706–13.
- 79 Dielman C, Laureys G, Meurs A, *et al.* Susac syndrome: a case report and PET imaging findings. *Acta Neurol Belg* 2009;109:226–30.
- 80 Puoti G, Bizzi A, Forloni G, *et al.* Sporadic human prion diseases: molecular insights and diagnosis. *Lancet Neurol* 2012;11:618–28.
- 81 Hayashi R, Hanyu N, Kuwabara T, *et al.* Serial computed tomographic and electroencephalographic studies in Creutzfeldt-Jakob disease. *Acta Neurol Scand* 1992;85:161–5.
- 82 Schroter A, Zerr I, Henkel K, *et al.* Magnetic resonance imaging in the clinical diagnosis of Creutzfeldt-Jakob disease. *Arch Neurol* 2000;57:1751–7.
- 83 Shiga Y, Miyazawa K, Sato S, *et al.* Diffusion-weighted MRI abnormalities as an early diagnostic marker for Creutzfeldt-Jakob disease. *Neurology* 2004;63:443–9.
- 84 Vitali P, Maccagnano E, Caverzasi E, *et al.* Diffusion-weighted MRI hyperintensity patterns differentiate CJD from other rapid dementias. *Neurology* 2011;76:1711–19.
- 85 Collins SJ, Sanchez-Juan P, Masters CL, *et al.* Determinants of diagnostic investigation sensitivities across the clinical spectrum of sporadic Creutzfeldt-Jakob disease. *Brain* 2006;129(Pt 9):2278–87.
- 86 Collie DA, Summers DM, Sellar RJ, *et al.* Diagnosing variant Creutzfeldt-Jakob disease with the pulvinar sign: MR imaging findings in 86 neuropathologically confirmed cases. *AJNR Am J Neuroradiol* 2003;24:1560–9.
- 87 Yi SH, Park KC, Yoon SS, *et al.* Relationship between clinical course and Diffusion-weighted MRI findings in sporadic Creutzfeldt-Jakob disease. *Neurol Sci* 2008;29:251–5.
- 88 Srivastava T, Kadam N. Bilateral putaminal hemorrhagic necrosis with rapid recovery of sensorium in a patient with methanol intoxication. *J Postgrad Med* 2013;59:243–4.
- 89 Ari S, Caca I, Kayabasi H. Bilateral complete optic atrophy and hemorrhagic infarction of the putamen caused by methanol intoxication. *Ann Ophthalmol (Skokie)* 2007;39:249–52.
- 90 Caparros-Lefebvre D, Policard J, Sengler C, *et al.* Bipallidal haemorrhage after ethylene glycol intoxication. *Neuroradiology* 2005;47:105–7.

**Supplementary Table 1. Neuroimaging findings in hypoxic-ischemic encephalopathy**

References	Total no. of patients	Imaging technique	Neuroimaging findings	Predictive value for poor outcome
<b>Hypoxic-ischemic encephalopathy</b>				
<b>CT</b>				
	69 patients			
1 prospective study [1]	53 patients out of 103	CT at a median 1 days after CPR and hypothermia	Global cerebral edema	False-positive rate 0% for death
1 case series [2]	16 patients	CT within 1 h after CPR	Putaminal, cortical and corticomedullary contrast	Higher putaminal, cortical and corticomedullary contrast was associated with CPC 4-5
<b>MRI</b>				
	269 patients			
1 prospective study [3]	27 patients	MRI in the first 15 days after CPR	Diffuse signal abnormalities in the cortex and subcortical areas or effacement of the sulci	All 8 patients with these MRI findings died; 1 of 2 patients who survived had subcortical signs of ischemia
1 retrospective study [4]	80 patients	MRI in first 7 days after CPR and hypothermia	Lower whole brain and regional median ADC	Patients with mRS >3 had significant lower median whole brain and regional ADC
1 prospective study [5]	22 patients	MRI at a median 4.1 (good outcome) and 9.8 days (poor outcome) after CPR	DWI and FLAIR multilobar, or diffuse lesion pattern with cortical involvement	False-positive rate 0% for CPC 4-5
1 prospective study [6]	40 patients out of 83	MRI in the first 7 days after CPR with hypothermia	ADC <650x10 <sup>6</sup> mm <sup>2</sup> /sec	False-positive rate 0% for death
1 prospective study [7]	22 patients out of 111	MRI at 48 hours after CPR with hypothermia	DWI with global ischemia or focal ischemia with total lesion volume >20mL	False positive rate 0% for CPC 3-5
1 prospective study [8]	39 patients	MRI in the first 5 days after CPR with hypothermia	Cortical and/or deep grey nuclei lesions	False positive rate 23% for GOS 1-3
1 retrospective study [9]	39 patients	MRI 1 to 150 days after CPR	T2 and DWI changes in the cerebral cortex and the deep grey matter	False positive rate 0% for Death, profound cognitive impairment including persistent vegetative state, minimally area states or severe physical impairment
<b>PET</b>				
	17 patients			
1 case series [10]	17 patients	Patients with vegetative states (time after CPR not provided)	Hypometabolism frontal, parietal including the precuneus, in the posterior cingulate gyrus, and in the occipital areas. Hypermetabolism in the insulas, cerebellum, and brainstem	No clear evidence

CT = computed tomography; MRI = magnetic resonance imaging; PET = positron emission tomography; CPR = cardiopulmonary resuscitation; ADC = apparent diffusion coefficient; DWI = diffusion-weighted imaging; FLAIR = fluid attenuated inversion recovery; mRS =

modified ranking scale; CPC = cerebral performance category; GOS = Glasgow outcome scale

## References

1. Fugate JE, Wijdicks EF, Mandrekar J, et al. Predictors of neurologic outcome in hypothermia after cardiac arrest. *Ann Neurol* 2010;68(6):907-914.
2. Yanagawa Y, Un-no Y, Sakamoto T, et al. Cerebral density on CT immediately after a successful resuscitation of cardiopulmonary arrest correlates with outcome. *Resuscitation* 2005;64(1):97-101.
3. Wijdicks EF, Campeau NG, Miller GM. MR imaging in comatose survivors of cardiac resuscitation. *AJNR Am J Neuroradiol* 2001;22(8):1561-1565.
4. Wu O, Sorensen AG, Benner T, et al. Comatose patients with cardiac arrest: predicting clinical outcome with diffusion-weighted MR imaging. *Radiology* 2009;252(1):173-181.
5. Topcuoglu MA, Oguz KK, Buyukserbetci G, et al. Prognostic value of magnetic resonance imaging in post-resuscitation encephalopathy. *Intern Med* 2009;48(18):1635-1645.
6. Wijman CA, Mlynash M, Caulfield AF, et al. Prognostic value of brain diffusion-weighted imaging after cardiac arrest. *Ann Neurol* 2009;65(4):394-402.
7. Choi SP, Park KN, Park HK, et al. Diffusion-weighted magnetic resonance imaging for predicting the clinical outcome of comatose survivors after cardiac arrest: a cohort study. *Crit Care* 2010;14(1):R17.
8. Cronberg T, Rundgren M, Westhall E, et al. Neuron-specific enolase correlates with other prognostic markers after cardiac arrest. *Neurology* 2011;77(7):623-630.
9. Howard RS, Holmes PA, Siddiqui A, et al. Hypoxic-ischaemic brain injury: imaging and neurophysiology abnormalities related to outcome. *QJM* 2012;105(6):551-561.
10. Kim YW, Kim HS, An YS. Brain metabolism in patients with vegetative state after post-resuscitated hypoxic-ischemic brain injury: statistical parametric mapping analysis of F-18 fluorodeoxyglucose positron emission tomography. *Chin Med J (Engl)* 2013;126(5):888-894.

**Supplementary Table 2. Neuroimaging findings in encephalopathies with specific biochemical derangements**

Imaging techniques / References	Total no. of patients	Neuroimaging findings	Predictive value for poor outcome
<b>Uremic encephalopathy</b>			
<b>CT</b> 2 case series [1,2] 2 case reports [3,4]	7 patients	Hypodense basal ganglia and capsules	No clear evidence
<b>MRI</b> 3 case series [1,2,5] 6 case reports [3,4,6-9]	15 patients	- T2, FLAIR and DWI hyperintense basal ganglia, capsules and inconsistently in cortical areas - Additional involvement of white matter and cerebral peduncles, occipital lobes and thalami	No clear evidence
<b>MRS</b> 1 case report [10]	1 patient	Decrease of N-acetyl-aspartate and the presence of lactate	No clear evidence
<b>PET</b> 1 case series [11]	2 patients	Decreased glucose metabolism in basal ganglia	No clear evidence
<b>Hyperammonemic encephalopathy</b>			
<b>MRI</b> 2 case series [12,13]	7 patients	T2, FLAIR and DWI hyperintense cortical areas of the insula and the cingulum	No clear evidence
<b>MRS</b> 2 case reports [14,15]	2 patients	Increased glutamine and glutamate; low myoinositol and choline	No clear evidence
<b>Hypo-/hypernatremic encephalopathies (pontine or extrapontine myelinolysis)</b>			
<b>CT</b> 2 retrospective studies [16,17] 1 Case series [18]	48 patients	Normal in a few patients and hypodense pontine lesions in the others	No clear evidence
<b>MRI</b> 2 retrospective studies [16,17] 6 case series [18-23] 9 case reports [4,15,24-30]	136 patients	- T2, FLAIR and DWI hyperintense lesions of the pons. Less frequent lesions of the thalamus, midbrain, cortical gray matter, hippocampus, caudate, putamen, and middle cerebral peduncle - In 1 patient T2 hyperintensities characteristically were distributed along the crowns and sides of the cerebral gyri	No correlation between the lesion size and outcome
<b>SPECT</b> 2 case reports [31,32]	2 patients	Decreased striatal dopamine transporter binding and pontine hyperperfusion during recovery from pontine myelinolysis	No clear evidence
<b>Hypoglycemic encephalopathy</b>			
<b>CT</b> 1 case series [33] 1 case report [4]	5 patients	Enhancing, hypodense basal ganglia, cerebral cortex, hippocampus, and substantia nigra	No clear evidence
<b>MRI</b> 5 case series [33-37] 8 case reports [4,38-44]	41 patients	- T2 and FLAIR hyperintensities in the caudate, lenticular nuclei, cerebral cortex, substantia nigra, hippocampus, and internal capsules - In few patients DWI hyperintense white and deep gray matter and splenium of the corpus callosum	Associated with vegetative state or severe disability in two case series
<b>Hyperglycemic encephalopathy</b>			
<b>CT</b> 2 case reports [45,46] 1 case series [47]	11 patients	Hyperdense putamen and/or caudate nucleus or, in fewer patients, normal CT	No clear evidence
<b>MRI</b> 5 case series [47-51] 3 case reports [45,46,52]	31 patients	Uni- or bilateral T1 hyperintensities in the striatum (mostly the putamen)	No clear evidence
<b>SPECT</b> 1 case series [47]	3 patients	Hypoperfusion of the basal ganglia	No clear evidence

CT = computed tomography; MRI = magnetic resonance imaging; DWI = diffusion-weighted imaging; FLAIR = fluid attenuated inversion recovery; MRS = magnetic resonance spectroscopy; PET = positron emission tomography; SPECT = single photon emission computed tomography

## References

1. Wang HC, Brown P, Lees AJ. Acute movement disorders with bilateral basal ganglia lesions in uremia. *Mov Disord* 1998;13(6):952-957.
2. Lee EJ, Park JH, Ihn Y, et al. Acute bilateral basal ganglia lesions in diabetic uraemia: diffusion-weighted MRI. *Neuroradiology* 2007;49(12):1009-1013.
3. Sheu YL, Cheng SJ, Chen YM, et al. The syndrome of bilateral basal ganglia lesions in diabetic uremic patients presenting with a relapsing and remitting course: a case report. *Acta Neurol Taiwan* 2007;16(4):226-230.
4. Bathla G, Hegde AN. MRI and CT appearances in metabolic encephalopathies due to systemic diseases in adults. *Clin Radiol* 2012: epub ahead of print.
5. Lin JJ. Generalized chorea in the syndrome of acute bilateral basal ganglia lesions in patients with diabetic uremia. *J Clin Neurosci* 2011;18(9):1266-1268.
6. Park JH, Kim HJ, Kim SM. Acute chorea with bilateral basal ganglia lesions in diabetic uremia. *Can J Neurol Sci* 2007;34(2):248-250.
7. Pruss H, Siebert E, Masuhr F. Reversible cytotoxic brain edema and facial weakness in uremic encephalopathy. *J Neurol* 2009;256(8):1372-1373.
8. Schmidt M, Sitter T, Lederer SR, et al. Reversible MRI changes in a patient with uremic encephalopathy. *J Nephrol* 2001;14(5):424-427.
9. Kang E, Jeon SJ, Choi SS. Uremic encephalopathy with atypical magnetic resonance features on diffusion-weighted images. *Korean J Radiol* 2012;13(6):808-811.
10. Dicuonzo F, Di Fede R, Salvati A, et al. Acute extrapyramidal disorder with bilateral reversible basal ganglia lesions in a diabetic uremic patient: diffusion-weighted imaging and spectroscopy findings. *J Neurol Sci* 2010;293(1-2):119-121.
11. Wang HC, Hsu JL, Shen YY. Acute bilateral basal ganglia lesions in patients with diabetic uremia: an FDG-PET study. *Clin Nucl Med* 2004;29(8):475-478.
12. Takanashi J, Barkovich AJ, Cheng SF, et al. Brain MR imaging in acute hyperammonemic encephalopathy arising from late-onset ornithine transcarbamylase deficiency. *AJNR Am J Neuroradiol* 2003;24(3):390-393.
13. U King-Im J, Yu E, Bartlett E, et al. Acute hyperammonemic encephalopathy in adults: imaging findings. *AJNR Am J Neuroradiol* 2011;32(2):413-418.
14. Rovira A, Alonso J, Cordoba J. MR imaging findings in hepatic encephalopathy. *AJNR Am J Neuroradiol* 2008;29(9):1612-1621.
15. Sharma P, Eesa M, Scott JN. Toxic and acquired metabolic encephalopathies: MRI appearance. *AJR Am J Roentgenol* 2009;193(3):879-886.
16. Menger H, Jorg J. Outcome of central pontine and extrapontine myelinolysis (n = 44). *J Neurol* 1999;246(8):700-705.
17. Graff-Radford J, Fugate JE, Kaufmann TJ, et al. Clinical and radiologic correlations of central pontine myelinolysis syndrome. *Mayo Clin Proc* 2011;86(11):1063-1067.
18. Miller GM, Baker HL, Jr., Okazaki H, et al. Central pontine myelinolysis and its imitators: MR findings. *Radiology* 1988;168(3):795-802.

19. Karp BI, Laureno R. Pontine and extrapontine myelinolysis: a neurologic disorder following rapid correction of hyponatremia. *Medicine (Baltimore)* 1993;72(6):359-373.
20. Brunner JE, Redmond JM, Hagggar AM, et al. Central pontine myelinolysis and pontine lesions after rapid correction of hyponatremia: a prospective magnetic resonance imaging study. *Ann Neurol* 1990;27(1):61-66.
21. Yuh WT, Simonson TM, D'Alessandro MP, et al. Temporal changes of MR findings in central pontine myelinolysis. *AJNR Am J Neuroradiol* 1995;16(4 Suppl):975-977.
22. Forster A, Nolte I, Wenz H, et al. Value of diffusion-weighted imaging in central pontine and extrapontine myelinolysis. *Neuroradiology* 2012.
23. De Souza A, Desai PK. More often striatal myelinolysis than pontine? A consecutive series of patients with osmotic demyelination syndrome. *Neurol Res* 2012;34(3):262-271.
24. Chu K, Kang DW, Ko SB, et al. Diffusion-weighted MR findings of central pontine and extrapontine myelinolysis. *Acta Neurol Scand* 2001;104(6):385-388.
25. Ruzek KA, Campeau NG, Miller GM. Early diagnosis of central pontine myelinolysis with diffusion-weighted imaging. *AJNR Am J Neuroradiol* 2004;25(2):210-213.
26. Fleming JD, Babu S. Images in clinical medicine. Central pontine myelinolysis. *N Engl J Med* 2008;359(23):e29.
27. Gujjar A, Al-Mamari A, Jacob PC, et al. Extrapontine myelinolysis as presenting manifestation of adrenal failure: a case report. *J Neurol Sci* 2010;290(1-2):169-171.
28. Pietrini V, Mozzani F, Crafa P, et al. Central pontine and extrapontine myelinolysis despite careful correction of hyponatremia: clinical and neuropathological findings of a case. *Neurol Sci* 2010;31(2):227-230.
29. Rizvi I, Ahmad M, Gupta A, et al. Isolated extra pontine myelinolysis presenting as acute onset parkinsonism. *BMJ Case Rep* 2012;2012.
30. Juergenson I, Zappini F, Fiaschi A, et al. Teaching neuroimages: neuroradiologic findings in pontine and extrapontine myelinolysis: clue for the pathogenesis? *Neurology* 2012;78(1):e1-2.
31. Kim JS, Lee KS, Han SR, et al. Decreased striatal dopamine transporter binding in a patient with extrapontine myelinolysis. *Mov Disord* 2003;18(3):342-345.
32. Nishida Y, Ichikawa T. Pontine hyperperfusion during recovery from central pontine myelinolysis. *Intern Med* 2012;51(7):817-818.
33. Fujioka M, Okuchi K, Hiramatsu KI, et al. Specific changes in human brain after hypoglycemic injury. *Stroke* 1997;28(3):584-587.
34. Lo L, Tan AC, Umapathi T, et al. Diffusion-weighted MR imaging in early diagnosis and prognosis of hypoglycemia. *AJNR Am J Neuroradiol* 2006;27(6):1222-1224.
35. Kim JH, Choi JY, Koh SB, et al. Reversible splenial abnormality in hypoglycemic encephalopathy. *Neuroradiology* 2007;49(3):217-222.
36. Ma JH, Kim YJ, Yoo WJ, et al. MR imaging of hypoglycemic encephalopathy: lesion distribution and prognosis prediction by diffusion-weighted imaging. *Neuroradiology* 2009;51(10):641-649.
37. Lim CC, Gan R, Chan CL, et al. Severe hypoglycemia associated with an illegal sexual enhancement product adulterated with glibenclamide: MR imaging findings. *Radiology* 2009;250(1):193-201.
38. Finelli PF. Diffusion-weighted MR in hypoglycemic coma. *Neurology* 2001;57(5):933.
39. Aoki T, Sato T, Hasegawa K, et al. Reversible hyperintensity lesion on diffusion-weighted MRI in hypoglycemic coma. *Neurology* 2004;63(2):392-393.

40. Bottcher J, Kunze A, Kurrat C, et al. Localized reversible reduction of apparent diffusion coefficient in transient hypoglycemia-induced hemiparesis. *Stroke* 2005;36(3):e20-22.
41. Cordonnier C, Oppenheim C, Lamy C, et al. Serial diffusion and perfusion-weighted MR in transient hypoglycemia. *Neurology* 2005;65(1):175.
42. Albayram S, Ozer H, Gokdemir S, et al. Reversible reduction of apparent diffusion coefficient values in bilateral internal capsules in transient hypoglycemia-induced hemiparesis. *AJNR Am J Neuroradiol* 2006;27(8):1760-1762.
43. Maruya J, Endoh H, Watanabe H, et al. Rapid improvement of diffusion-weighted imaging abnormalities after glucose infusion in hypoglycaemic coma. *J Neurol Neurosurg Psychiatry* 2007;78(1):102-103.
44. Terakawa Y, Tsuyuguchi N, Nunomura K, et al. Reversible diffusion-weighted imaging changes in the splenium of the corpus callosum and internal capsule associated with hypoglycemia - case report. *Neurol Med Chir (Tokyo)* 2007;47(10):486-488.
45. Nakagawa T, Mitani K, Nagura H, et al. [Chorea-ballism associated with nonketotic hyperglycemia and presenting with bilateral hyperintensity of the putamen on MR T1-weighted images--a case report]. *Rinsho Shinkeigaku* 1994;34(1):52-55.
46. Nagai C, Kato T, Katagiri T, et al. Hyperintense putamen on T1-weighted MR images in a case of chorea with hyperglycemia. *AJNR Am J Neuroradiol* 1995;16(6):1243-1246.
47. Lai PH, Tien RD, Chang MH, et al. Chorea-ballismus with nonketotic hyperglycemia in primary diabetes mellitus. *AJNR Am J Neuroradiol* 1996;17(6):1057-1064.
48. Yahikozawa H, Hanyu N, Yamamoto K, et al. Hemiballism with striatal hyperintensity on T1-weighted MRI in diabetic patients: a unique syndrome. *J Neurol Sci* 1994;124(2):208-214.
49. Lee BC, Hwang SH, Chang GY. Hemiballismus-hemichorea in older diabetic women: a clinical syndrome with MRI correlation. *Neurology* 1999;52(3):646-648.
50. Lin JJ, Lin GY, Shih C, et al. Presentation of striatal hyperintensity on T1-weighted MRI in patients with hemiballism-hemichorea caused by non-ketotic hyperglycemia: report of seven new cases and a review of literature. *J Neurol* 2001;248(9):750-755.
51. Lee EJ, Choi JY, Lee SH, et al. Hemichorea-hemiballism in primary diabetic patients: MR correlation. *J Comput Assist Tomogr* 2002;26(6):905-911.
52. Ohara S, Nakagawa S, Tabata K, et al. Hemiballism with hyperglycemia and striatal T1-MRI hyperintensity: an autopsy report. *Mov Disord* 2001;16(3):521-525.

**Supplementary Table 3. Neuroimaging findings in specific clinical encephalopathy syndromes**

Imaging techniques / References	Total no. of patients	Neuroimaging findings	Predictive value for poor outcome
<b>Hepatic encephalopathy</b>			
<b>CT</b> 1 case series [1]	17 patients	Normal	No clear evidence
<b>MRI</b> 1 prospective study [2] 4 retrospective studies [3-6] 5 case series [1,7-10] 1 case report [11]	290 patients	- T1 hyperintensities in the globus pallidus and, less frequent, in the substantia nigra and the midbrain tegmentum - FLAIR and DWI hyperintense thalami, posterior limbs of the internal capsule, periventricular region, dorsal brain stem, and diffuse cortical involvement in 1 study of 20 patients - Connectivity: decreased in the caudate of the anterior/middle cingulate gyrus; increased in the caudate of the left motor cortex; reduced between the putamen and the anterior cingulate gyrus, right insular lobe, inferior frontal gyrus, left parahippocampal gyrus, and the anterior lobe of the right cerebellum; increased between the putamen and right middle temporal gyrus	Correlations between the cortico-striatal connectivity and neuropsychological performances, but not between the striatal connectivity and globus pallidus signal intensity
<b>MRS</b> 2 case reports [10,12]	2 patients	- Increased glutamate/glutamine ratio and low myoinositol and choline - Diminished choline and elevated glutamate/glutamine ratio in the parietooccipital cortex	No clear evidence
<b>SPECT</b> 2 case reports [13,14]	2 patients	- High blood flow in the cerebellum, basal ganglia and cerebral cortex - Alteration of striatal D2-receptor binding and dopamine re-uptake	No clear evidence
<b>PET</b> 1 prospective study [15] 1 case report [16]	41 patients	- Hypoperfusion of the superior and middle frontal gyri, and inferior parietal lobules - Increased expression of peripheral benzodiazepine binding sites prefrontal and striatal in cirrhotic patients	No clear evidence
<b>Wernicke's encephalopathy</b>			
<b>CT</b> 1 retrospective study [17] 1 case series [18] 4 case reports [19-22]	22 patients	Hypodense paraventricular thalamic regions with or without contrast enhancement and, less frequent, hypodense periaqueductal regions, tectum of the midbrain, and tegmentum of the pons	No clear evidence
<b>MRI</b> 1 prospective study [23] 4 retrospective studies [17,24-26] 2 case series [18,27] 5 case reports [21,22,28-30]	202 patients	- T2 and FLAIR hyperintense periaqueduct and medial thalamic regions. Less frequent hyperintense mamillary bodies, periaqueductal region, hypothalamus, tectum, and cerebellum - In 1 study 78% of patients with Wernicke's encephalopathy had smaller mamillary bodies than controls - Contrast-enhanced mamillary bodies were related to alcohol abuse - Atrophic mamillary bodies and cerebellar vermis (chronic phase)	No clear evidence
<b>MRS</b> 2 case reports [30,31]	2 patients	Thalamic lactate increase and low N-acetyl-aspartate/creatine	No clear evidence
<b>SPECT</b> 1 case report [32]	1 patient	Hypoperfusion fronto-parietal and in the right basal ganglia	No clear evidence
<b>Posterior reversible encephalopathy</b>			
<b>CT</b> 1 retrospective study [33] 2 case reports [34,35]	69 patients	- Hypodensities in the parietooccipital subcortical white matter and cerebellum with increased cerebral blood volume, blood flow, and reduced time to peak mainly in the posterior vascular distribution (Features of PRES in 45%, unspecific in 33% and normal in 22%) - In patients with PRES on MRI, CT was negative/unspecific in 66%	No clear evidence
<b>MRI</b> 4 retrospective studies [33,36-38] 2 case series [39,40]	355 patients	- T2, FLAIR, and DWI hyperintensities in the posterior circulation areas and, less frequent, in the anterior circulation structures. ADC values in areas of abnormal T2 signal were high	More extensive T2 signal abnormalities were seen with poor

7 case reports [11,34,41-45]		- Contrast-enhancement, restrictions on DWI and ADC	outcome
<b>MRS</b> 2 case series [39,46] 1 case report [41]	13 patients	Decrease in N-acetyl-aspartate in patients with normal MRI or reversible MRI changes and only minimal elevation of choline	No clear evidence
<b>Acute disseminated encephalomyelitis</b>			
<b>CT</b> 11 retrospective study [47]	12 patients	Normal	No clear evidence
<b>MRI</b> 2 retrospective studies [47,48] 1 prospective study [49]	50 patients	- T2 and FLAIR with multiple brain lesions in the deep and subcortical white matter and in 1/3 in the brainstem and spinal cord with contrast enhancement - In the first week (acute phase) DWI with restricted diffusion, and later (subacute phase) with increased diffusion	No clear evidence
<b>MRS</b> 1 retrospective study [48]	8 patients	Decreased N-acetyl-aspartate in regions corresponding to the T2 signal intensity in the subacute phase	No clear evidence
<b>Paraneoplastic limbic encephalitis</b>			
<b>CT</b> 5 case reports [50-54]	5 patients	Normal	No clear evidence
<b>MRI</b> 2 retrospective studies [55,56] 10 case reports [50-54,57-61]	83 patients	- T2 and FLAIR hyperintensities with mesial temporal contrast enhancement in >50% and/or atrophy - Subcortical regions, the cerebellum or brainstem may be involved	No clear evidence
<b>PET</b> 4 case reports [50,58,62,63]	4 patients	PET may reveal increased metabolism mesial temporal	No clear evidence
<b>Autoimmune limbic encephalitis</b>			
<b>CT</b> 4 case reports [64-67]	4 patients	Normal	No clear evidence
<b>MRI</b> NMDA 1 retrospective study [68] 1 case series [69] 9 case reports [65,66,70-76] SREAT 4 retrospective studies [77-80] 10 case reports [67,81-87]	158 patients	- In NMDAR-antibody mediated limbic encephalitis, MRI is mostly (50%) normal but can show T2 and FLAIR hyperintensities temporal and rarely extratemporal. MRI is used to exclude other causes of encephalopathy - In SREAT, T2 and FLAIR can rarely resemble acute demyelinating encephalomyelitis or show hippocampal or multifocal hyperintensities	No clear evidence
<b>MRS</b> 2 case reports [82,88]	2 patients	In SREAT, decreased N-acetyl-aspartate, myo-inositol peaks, elevations in lipid, lactate, glutamate/glutamine and choline peaks support inflammation	No clear evidence
<b>SPECT</b> 1 retrospective study [79] 4 case reports [89-92]	16 patients	- In NMDAR-antibody mediated limbic encephalitis, abnormal multifocal cerebral blood flow - In SREAT, decreased tracer uptake in the striatum and global cortical hypoperfusion	No clear evidence
<b>Herpes simplex encephalitis</b>			
<b>CT</b> 3 retrospective studies [93-95] 1 case series [96] 2 case reports [97,98]	121 patients	Usually normal, but can characteristically show reduced attenuation in the temporal lobes after the first week of the disease	Lesions on CT are predictive of prolonged course of disease
<b>MRI</b> 5 retrospective studies [95,99-102] 4 case series [96,103-105] 22 case reports [97,98,106-125]	298 patients	- T2, FLAIR, and DWI hyperintensities in the medial temporal lobes, the orbital surface of the frontal lobes, the insular cortex, the angular gyrus, and in the insulas early in the course. Rarely the thalami and insulas may be involved. - Abnormal areas may show enhancement with gadolinium - Midline shift may be present with large cerebral edema	The extent of brain involvement is an independent risk factor for poor prognosis
<b>SPECT</b> 1 case series [96] 1 case report [97]	3 patients	Increased tracer accumulation which reflects hyperperfusion possibly earlier than pathologic signals appear on MRI	No clear evidence
<b>Susac's syndrome</b>			

<b>CT</b> 1 case report [126]	1 patient	Does not reveal any of the specific structural abnormalities, but can demonstrate foci of subtle low attenuation in the corpus callosum	No clear evidence
<b>MRI</b> 4 case series [127-130] 12 case reports [126,131-141]	53 patients	<ul style="list-style-type: none"> <li>- T2 and FLAIR hyperintensities in the corpus callosum, which is always involved</li> <li>- Any part of the corpus callosum can be involved, but predominately the central fibers are showing microinfarcts that are typically small but may sometimes be large</li> <li>- Foci in the corpus callosum may enhance following gadolinium administration and there can be restricted diffusion with corresponding low signal intensity on the ADC map</li> <li>- Spinal cord involvement is rare but exists</li> <li>- Subsequently, central callosal holes arise</li> </ul>	No clear evidence
<b>PET</b> 1 case report [142]	1 patient	Marked hypometabolism in the frontal, parietal and temporal lobes – an unspecific pattern that can be mistaken as ADEM	No clear evidence
<b>Creutzfeldt-Jakob disease</b>			
<b>CT</b> 3 case series [143-145]	11 patients	Non-specific generalized cortical and subcortical atrophy in the later phases of disease	No clear evidence
<b>MRI</b> 13 retrospective studies [146-158] 12 case series [144,159-169] 26 case reports [170-197]	3393 patients	<ul style="list-style-type: none"> <li>- T2 and FLAIR hyperintensities in the cerebral cortex and lesions in the putamen and caudate head isointense to cortex</li> <li>- Less frequently, hyperintensity can be detected in the globus pallidus, thalamus, the deep white matter, and the cerebral and cerebellar cortex. Laminar lesions may be observed in the cerebral cortex and cerebellum</li> <li>- DWI is most sensitive in early stages uncovering the altered diffusion in the regions mentioned above</li> <li>- In vCJD symmetrical hyperintensities of the pulvinar thalami (relative to the cortex and especially the anterior part of the putamen) are characteristic and known as the “pulvinar sign”</li> </ul>	Patients with cortical plus basal ganglia hyperintensity have shorter interval from symptom onset to akinetic mutism than those with isolated cortical ribbon hyperintensity
<b>MRS</b> 1 case report [198]	1 patients	Decreased N-acetyl-aspartate and slightly increased levels of myoinositol in the striatum and the insular cortex.	No clear evidence
<b>SPECT</b> 1 case report [172]	1 patient	Hypoperfusion in the cerebral cortex	No clear evidence
<b>PET</b> 1 case series [151] 1 case report [176]	15 patients	Hypometabolism in the cerebral cortex and the basal ganglia	No clear evidence

CT = computed tomography; MRI = magnetic resonance imaging; DWI = diffusion-weighted imaging; FLAIR = fluid attenuated inversion recovery; MRS = magnetic resonance spectroscopy; SPECT = single photon emission computed tomography; PET = positron emission tomography; ADEM = acute disseminated encephalomyelitis; NMDAR = N-methyl-D-aspartate receptor; SREAT = steroid responsive encephalitis with autoimmune thyroiditis

## References

1. Sun QJ, Wang AH, Zhu MJ, et al. [EEG, CT and MRI findings in hepatic encephalopathy]. Nan Fang Yi Ke Da Xue Xue Bao 2007;27(11):1759-1761.
2. Zhu XQ, Chen HJ, Wang Y, et al. Aberrant Resting-State Corticostriatal Functional Connectivity in Cirrhotic Patients with Hyperintense Globus Pallidus on T1-Weighted MR Imaging. PLoS One 2012;7(11):e48886.

3. Pujol A, Pujol J, Graus F, et al. Hyperintense globus pallidus on T1-weighted MRI in cirrhotic patients is associated with severity of liver failure. *Neurology* 1993;43(1):65-69.
4. Krieger S, Jauss M, Jansen O, et al. Neuropsychiatric profile and hyperintense globus pallidus on T1-weighted magnetic resonance images in liver cirrhosis. *Gastroenterology* 1996;111(1):147-155.
5. Burkhard PR, Delavelle J, Du Pasquier R, et al. Chronic parkinsonism associated with cirrhosis: a distinct subset of acquired hepatocerebral degeneration. *Arch Neurol* 2003;60(4):521-528.
6. McKinney AM, Lohman BD, Sarikaya B, et al. Acute hepatic encephalopathy: diffusion-weighted and fluid-attenuated inversion recovery findings, and correlation with plasma ammonia level and clinical outcome. *AJNR Am J Neuroradiol* 2010;31(8):1471-1479.
7. Inoue E, Hori S, Narumi Y, et al. Portal-systemic encephalopathy: presence of basal ganglia lesions with high signal intensity on MR images. *Radiology* 1991;179(2):551-555.
8. Butterworth RF, Spahr L, Fontaine S, et al. Manganese toxicity, dopaminergic dysfunction and hepatic encephalopathy. *Metab Brain Dis* 1995;10(4):259-267.
9. Jog MS, Lang AE. Chronic acquired hepatocerebral degeneration: case reports and new insights. *Mov Disord* 1995;10(6):714-722.
10. Rovira A, Alonso J, Cordoba J. MR imaging findings in hepatic encephalopathy. *AJNR Am J Neuroradiol* 2008;29(9):1612-1621.
11. Bathla G, Hegde AN. MRI and CT appearances in metabolic encephalopathies due to systemic diseases in adults. *Clin Radiol* 2012:epub ahead of print.
12. Sharma P, Eesa M, Scott JN. Toxic and acquired metabolic encephalopathies: MRI appearance. *AJR Am J Roentgenol* 2009;193(3):879-886.
13. Kohira I, Matsuo E, Shiro Y, et al. Hepatic encephalopathy with increased cerebral blood flow in SPECT and MRI abnormalities in the basal ganglia. *Jpn J Psychiatry Neurol* 1994;48(1):33-36.
14. Weissenborn K, Berding G, Kostler H. Altered striatal dopamine D2 receptor density and dopamine transport in a patient with hepatic encephalopathy. *Metab Brain Dis* 2000;15(3):173-178.
15. Nakagawa Y, Matsumura K, Iwasa M, et al. Single photon emission computed tomography and statistical parametric mapping analysis in cirrhotic patients with and without minimal hepatic encephalopathy. *Ann Nucl Med* 2004;18(2):123-129.
16. Cagnin A, Taylor-Robinson SD, Forton DM, et al. In vivo imaging of cerebral "peripheral benzodiazepine binding sites" in patients with hepatic encephalopathy. *Gut* 2006;55(4):547-553.
17. Antunez E, Estruch R, Cardenal C, et al. Usefulness of CT and MR imaging in the diagnosis of acute Wernicke's encephalopathy. *AJR Am J Roentgenol* 1998;171(4):1131-1137.
18. Gallucci M, Bozzao A, Splendiani A, et al. Wernicke encephalopathy: MR findings in five patients. *AJNR Am J Neuroradiol* 1990;11(5):887-892.
19. Mensing JW, Hoogland PH, Slooff JL. Computed tomography in the diagnosis of Wernicke's encephalopathy: a radiological-neuropathological correlation. *Ann Neurol* 1984;16(3):363-365.
20. McDowell JR, LeBlanc HJ. Computed tomographic findings in Wernicke-Korsakoff syndrome. *Arch Neurol* 1984;41(4):453-454.
21. Kitaguchi T, Kobayashi T, Tobimatsu S, et al. Computed tomography and magnetic resonance imaging in a young patient with Wernicke's encephalopathy. *J Neurol* 1987;234(6):449-450.
22. Yokote K, Miyagi K, Kuzuhara S, et al. Wernicke encephalopathy: follow-up study by CT and MR. *J Comput Assist Tomogr* 1991;15(5):835-838.

23. Park SH, Kim M, Na DL, et al. Magnetic resonance reflects the pathological evolution of Wernicke encephalopathy. *J Neuroimaging* 2001;11(4):406-411.
24. Charness ME, DeLaPaz RL. Mamillary body atrophy in Wernicke's encephalopathy: antemortem identification using magnetic resonance imaging. *Ann Neurol* 1987;22(5):595-600.
25. Zuccoli G, Santa Cruz D, Bertolini M, et al. MR imaging findings in 56 patients with Wernicke encephalopathy: nonalcoholics may differ from alcoholics. *AJNR Am J Neuroradiol* 2009;30(1):171-176.
26. Zuccoli G, Gallucci M, Capellades J, et al. Wernicke encephalopathy: MR findings at clinical presentation in twenty-six alcoholic and nonalcoholic patients. *AJNR Am J Neuroradiol* 2007;28(7):1328-1331.
27. Doherty MJ, Watson NF, Uchino K, et al. Diffusion abnormalities in patients with Wernicke encephalopathy. *Neurology* 2002;58(4):655-657.
28. Yamashita M, Yamamoto T. Wernicke encephalopathy with symmetric pericentral involvement: MR findings. *J Comput Assist Tomogr* 1995;19(2):306-308.
29. Bae SJ, Lee HK, Lee JH, et al. Wernicke's encephalopathy: atypical manifestation at MR imaging. *AJNR Am J Neuroradiol* 2001;22(8):1480-1482.
30. Murata T, Fujito T, Kimura H, et al. Serial MRI and (1)H-MRS of Wernicke's encephalopathy: report of a case with remarkable cerebellar lesions on MRI. *Psychiatry Res* 2001;108(1):49-55.
31. Rugilo CA, Uribe Roca MC, Zurru MC, et al. Proton MR spectroscopy in Wernicke encephalopathy. *AJNR Am J Neuroradiol* 2003;24(5):952-955.
32. Celik Y, Kaya M. Brain SPECT findings in Wernicke's encephalopathy. *Neurol Sci* 2004;25(1):23-26.
33. Bartynski WS, Boardman JF. Distinct imaging patterns and lesion distribution in posterior reversible encephalopathy syndrome. *AJNR Am J Neuroradiol* 2007;28(7):1320-1327.
34. Hodnett P, Coyle J, O'Regan K, et al. PRES (posterior reversible encephalopathy syndrome), a rare complication of tacrolimus therapy. *Emerg Radiol* 2009;16(6):493-496.
35. Hedna VS, Stead LG, Bidari S, et al. Posterior reversible encephalopathy syndrome (PRES) and CT perfusion changes. *Int J Emerg Med* 2012;5:12.
36. Covarrubias DJ, Luetmer PH, Campeau NG. Posterior reversible encephalopathy syndrome: prognostic utility of quantitative diffusion-weighted MR images. *AJNR Am J Neuroradiol* 2002;23(6):1038-1048.
37. McKinney AM, Short J, Truwit CL, et al. Posterior reversible encephalopathy syndrome: incidence of atypical regions of involvement and imaging findings. *AJR Am J Roentgenol* 2007;189(4):904-912.
38. Fugate JE, Claassen DO, Cloft HJ, et al. Posterior reversible encephalopathy syndrome: associated clinical and radiologic findings. *Mayo Clin Proc* 2010;85(5):427-432.
39. Sengar AR, Gupta RK, Dhanuka AK, et al. MR imaging, MR angiography, and MR spectroscopy of the brain in eclampsia. *AJNR Am J Neuroradiol* 1997;18(8):1485-1490.
40. Hugonnet E, Da Ines D, Boby H, et al. Posterior reversible encephalopathy syndrome (PRES): Features on CT and MR imaging. *Diagn Interv Imaging* 2012.
41. Russell MT, Nassif AS, Cacayorin ED, et al. Gemcitabine-associated posterior reversible encephalopathy syndrome: MR imaging and MR spectroscopy findings. *Magn Reson Imaging* 2001;19(1):129-132.
42. Lamy C, Oppenheim C, Meder JF, et al. Neuroimaging in posterior reversible encephalopathy syndrome. *J Neuroimaging* 2004;14(2):89-96.
43. Bartynski WS. Posterior reversible encephalopathy syndrome, part 1: fundamental imaging and clinical features. *AJNR Am J Neuroradiol* 2008;29(6):1036-1042.

44. Sutter R, Mengiardi B, Lyrer P, et al. Posterior reversible encephalopathy as the initial manifestation of a Guillain-Barre syndrome. *Neuromuscul Disord* 2009;19(10):709-710.
45. Siddiqui TS, Irfan ul H, Rehman B, et al. Posterior reversible encephalopathy syndrome (PRES). *J Coll Physicians Surg Pak* 2012;22(3):168-170.
46. Eichler FS, Wang P, Wityk RJ, et al. Diffuse metabolic abnormalities in reversible posterior leukoencephalopathy syndrome. *AJNR Am J Neuroradiol* 2002;23(5):833-837.
47. Caldemeyer KS, Smith RR, Harris TM, et al. MRI in acute disseminated encephalomyelitis. *Neuroradiology* 1994;36(3):216-220.
48. Balasubramanya KS, Kovoor JM, Jayakumar PN, et al. Diffusion-weighted imaging and proton MR spectroscopy in the characterization of acute disseminated encephalomyelitis. *Neuroradiology* 2007;49(2):177-183.
49. Campi A, Filippi M, Comi G, et al. Acute transverse myelopathy: spinal and cranial MR study with clinical follow-up. *AJNR Am J Neuroradiol* 1995;16(1):115-123.
50. Fujimoto S, Yamaguchi Y, Gotanda H, et al. [A case of limbic encephalitis with small cell lung carcinoma in which the cognitive function improved and redeteriorated during tumor therapy]. *Nihon Ronen Igakkai Zasshi* 2010;47(1):79-85.
51. Dabbeche C, Guyon D, Loubes-Lacroix F, et al. [Paraneoplastic limbic encephalitis associated with epidermoid lung carcinoma]. *J Neuroradiol* 2005;32(4):278-280.
52. Fischer B, Kalden P, Urban PP, et al. [Paraneoplastic limbic encephalitis in small cell lung carcinoma]. *Pneumologie* 2004;58(5):316-319.
53. Rimmelin A, Sellal F, Morand G, et al. [Imaging of limbic paraneoplastic encephalitis]. *J Radiol* 1997;78(1):73-76.
54. Lacomis D, Khoshbin S, Schick RM. MR imaging of paraneoplastic limbic encephalitis. *J Comput Assist Tomogr* 1990;14(1):115-117.
55. Gultekin SH, Rosenfeld MR, Voltz R, et al. Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings and tumour association in 50 patients. *Brain* 2000;123 ( Pt 7):1481-1494.
56. Lawn ND, Westmoreland BF, Kiely MJ, et al. Clinical, magnetic resonance imaging, and electroencephalographic findings in paraneoplastic limbic encephalitis. *Mayo Clin Proc* 2003;78(11):1363-1368.
57. Said S, Cooper CJ, Reyna E, et al. Paraneoplastic limbic encephalitis, an uncommon presentation of a common cancer: Case report and discussion. *Am J Case Rep* 2013;14:391-394.
58. Maffione AM, Chondrogiannis S, Ferretti A, et al. Correlative imaging with (18)F-FDG PET/CT and MRI in paraneoplastic limbic encephalitis. *Clin Nucl Med* 2013;38(6):463-464.
59. Kawashima S, Okita K, Yamawaki T, et al. [Case of paraneoplastic limbic encephalitis associated with malignant B cell lymphoma]. *Brain Nerve* 2009;61(2):208-212.
60. Launay M, Bozzolo E, Venissac N, et al. [Paraneoplastic limbic encephalitis with positive anti-R1 antibodies and mediastinal seminoma]. *Rev Neurol (Paris)* 2008;164(6-7):612-619.
61. Barnett M, Prosser J, Sutton I, et al. Paraneoplastic brain stem encephalitis in a woman with anti-Ma2 antibody. *J Neurol Neurosurg Psychiatry* 2001;70(2):222-225.
62. Kunze A, Drescher R, Kaiser K, et al. Serial FDG PET/CT in Autoimmune Encephalitis With Faciobrachial Dystonic Seizures. *Clin Nucl Med* 2014.
63. Markakis I, Papathanasiou A, Papageorgiou E, et al. Paraneoplastic limbic encephalitis resembling acute herpetic encephalitis. *Case Rep Neurol Med* 2013;2013:608643.

64. Kuo YL, Tsai HF, Lai MC, et al. Anti-NMDA receptor encephalitis with the initial presentation of psychotic mania. *J Clin Neurosci* 2012;19(6):896-898.
65. Bayreuther C, Bourg V, Dellamonica J, et al. Complex partial status epilepticus revealing anti-NMDA receptor encephalitis. *Epileptic Disord* 2009;11(3):261-265.
66. Sansing LH, Tuzun E, Ko MW, et al. A patient with encephalitis associated with NMDA receptor antibodies. *Nat Clin Pract Neurol* 2007;3(5):291-296.
67. Ryan SA, Kennedy C, Harrington HJ. Steroid-responsive encephalopathy associated with autoimmune thyroiditis presenting as confusion, dysphasia, and myoclonus. *Case Rep Med* 2012;2012:782127.
68. Song L, Liu AH. [Anti-N-methyl-D-aspartic acid receptor encephalitis: clinical analysis of 7 cases]. *Zhonghua Yi Xue Za Zhi* 2013;93(31):2508-2510.
69. Iizuka T, Sakai F, Ide T, et al. Anti-NMDA receptor encephalitis in Japan: long-term outcome without tumor removal. *Neurology* 2008;70(7):504-511.
70. Johnson N, Henry C, Fessler AJ, et al. Anti-NMDA receptor encephalitis causing prolonged nonconvulsive status epilepticus. *Neurology* 2010;75(16):1480-1482.
71. Herrero-Velazquez S, Luis Guerrero-Peral A, Gamez-Leyva G, et al. [Encephalitis due to antibodies against the NMDA receptor. A case report of a female patient with no associated tumour and a literature review]. *Rev Neurol* 2010;50(11):661-666.
72. Ito Y, Abe T, Tomioka R, et al. [Anti-NMDA receptor encephalitis during pregnancy]. *Rinsho Shinkeigaku* 2010;50(2):103-107.
73. Labate A, Irani SR, Vincent A, et al. Anti-NMDA receptor encephalitis: a video case report. *Epileptic Disord* 2009;11(3):267-269.
74. Iizuka T, Hara A. [Anti-NMDA receptor antibody-mediated encephalitis/encephalopathy]. *Rinsho Byori* 2009;57(3):252-261.
75. Henry C, Husson H, de Broucker T. [Autoimmune limbic encephalitis with anti-NMDA receptor antibodies and ovarian teratoma: a treatable form of paraneoplastic limbic encephalitis]. *Rev Neurol (Paris)* 2009;165(1):70-75.
76. Novillo-Lopez ME, Rossi JE, Dalmau J, et al. Treatment-responsive subacute limbic encephalitis and NMDA receptor antibodies in a man. *Neurology* 2008;70(9):728-729.
77. Castillo P, Woodruff B, Caselli R, et al. Steroid-responsive encephalopathy associated with autoimmune thyroiditis. *Arch Neurol* 2006;63(2):197-202.
78. Yoneda M. [Diagnosis and treatments of Hashimoto's encephalopathy]. *Rinsho Shinkeigaku* 2012;52(11):1240-1242.
79. Aupy J, Collongues N, Blanc F, et al. [Autoimmune encephalitis, clinical, radiological and immunological data]. *Rev Neurol (Paris)* 2013;169(2):142-153.
80. Tang Y, Xing Y, Lin MT, et al. Hashimoto's encephalopathy cases: Chinese experience. *BMC Neurol* 2012;12:60.
81. Mahad DJ, Staugaitis S, Ruggieri P, et al. Steroid-responsive encephalopathy associated with autoimmune thyroiditis and primary CNS demyelination. *J Neurol Sci* 2005;228(1):3-5.
82. Su TH, Jin EH, He W. Hashimoto encephalopathy: a case report with proton MR spectroscopic findings. *Chin Med J (Engl)* 2011;124(20):3420-3422.
83. Yamaguchi Y, Wada M, Tanji H, et al. Steroid-responsive thalamic lesions accompanying microbleeds in a case of Hashimoto's encephalopathy with autoantibodies against alpha-enolase. *Intern Med* 2013;52(11):1249-1253.

84. Chang T, Riffsy MT, Gunaratne PS. Hashimoto encephalopathy: clinical and MRI improvement following high-dose corticosteroid therapy. *Neurologist* 2010;16(6):394-396.
85. Chen N, Qin W, Wei C, et al. Time course of Hashimoto's encephalopathy revealed by MRI: report of two cases. *J Neurol Sci* 2011;300(1-2):169-172.
86. Nayak HK, Daga MK, Kumar R, et al. A series report of autoimmune hypothyroidism associated with Hashimoto's encephalopathy: an under diagnosed clinical entity with good prognosis. *BMJ Case Rep* 2010;2010.
87. Aydin-Ozemir Z, Tuzun E, Baykan B, et al. Autoimmune thyroid encephalopathy presenting with epilepsia partialis continua. *Clin EEG Neurosci* 2006;37(3):204-209.
88. Zhao W, Li J, Wang J, et al. A case of Hashimoto encephalopathy: clinical manifestation, imaging, pathology, treatment, and prognosis. *Neurologist* 2011;17(3):141-143.
89. Hsu CS, Wu YC, Lu MK, et al. 99mTc ECD and 99mTc TRODAT-1 SPECT in Hashimoto encephalopathy. *Clin Nucl Med* 2012;37(4):e86-88.
90. Fuertes J, Garcia-Burillo A, Castell-Conesa J, et al. Functional neuroimaging in Hashimoto's encephalitis: a physiopathological imaging? *Eur J Nucl Med Mol Imaging* 2009;36(4):726.
91. Llorens V, Gabilondo I, Gomez-Esteban JC, et al. Abnormal multifocal cerebral blood flow on Tc-99m HMPAO SPECT in a patient with anti-NMDA-receptor encephalitis. *J Neurol* 2010;257(9):1568-1569.
92. De Holanda NC, de Lima DD, Cavalcanti TB, et al. Hashimoto's encephalopathy: systematic review of the literature and an additional case. *J Neuropsychiatry Clin Neurosci* 2011;23(4):384-390.
93. Riancho J, Delgado-Alvarado M, Sedano MJ, et al. Herpes simplex encephalitis: clinical presentation, neurological sequelae and new prognostic factors. Ten years of experience. *Neurol Sci* 2013;34(10):1879-1881.
94. Taira N, Kamei S, Morita A, et al. Predictors of a prolonged clinical course in adult patients with herpes simplex virus encephalitis. *Intern Med* 2009;48(2):89-94.
95. Mekan SF, Wasay M, Khelaeni B, et al. Herpes simplex encephalitis: analysis of 68 cases from a tertiary care hospital in Karachi, Pakistan. *J Pak Med Assoc* 2005;55(4):146-148.
96. Hasegawa Y, Morishita M, Ikeda T, et al. Early diagnosis of herpes simplex virus encephalitis by single photon emission computed tomography (SPECT) in patients with normal MRI. *Rinsho Shinkeigaku* 1996;36(3):475-480.
97. Zajkowska JM, Ustymowicz A, Hermanowska-Szpakowicz T. [Difficulties in early diagnosis of Herpes simplex encephalitis]. *Pol Merkur Lekarski* 2005;19(113):719-722.
98. Jablkowski M, Kolasa P, Szubert W, et al. Herpes simplex encephalitis: a case report. *Med Sci Monit* 2004;10(8):CS41-45.
99. Sili U, Kaya A, Mert A, et al. Herpes simplex virus encephalitis: Clinical manifestations, diagnosis and outcome in 106 adult patients. *J Clin Virol* 2014.
100. Sheybani F, Arabikhan HR, Naderi HR. Herpes Simplex Encephalitis (HSE) and its outcome in the Patients who were Admitted to a Tertiary Care Hospital in Mashhad, Iran, over a 10-year Period. *J Clin Diagn Res* 2013;7(8):1626-1628.
101. Sawlani V. Diffusion-weighted imaging and apparent diffusion coefficient evaluation of herpes simplex encephalitis and Japanese encephalitis. *J Neurol Sci* 2009;287(1-2):221-226.
102. Riera-Mestre A, Gubieras L, Martinez-Yelamos S, et al. Adult herpes simplex encephalitis: fifteen years' experience. *Enferm Infecc Microbiol Clin* 2009;27(3):143-147.

103. Hatipoglu HG, Sakman B, Yuksel E. Magnetic resonance and diffusion-weighted imaging findings of herpes simplex encephalitis. *Herpes* 2008;15(1):13-17.
104. Kuker W, Nagele T, Schmidt F, et al. Diffusion-weighted MRI in herpes simplex encephalitis: a report of three cases. *Neuroradiology* 2004;46(2):122-125.
105. Sener RN. Herpes simplex encephalitis: diffusion MR imaging findings. *Comput Med Imaging Graph* 2001;25(5):391-397.
106. Diamond EL, Hatzoglou V, Santomaso B, et al. Temporal lobe meningioma with ipsilateral herpes simplex encephalitis. *Neurohospitalist* 2014;4(1):42-43.
107. Ahmed R, Kiani IG, Shah F, et al. Herpes simplex encephalitis presenting with normal CSF analysis. *J Coll Physicians Surg Pak* 2013;23(10):815-817.
108. Navin P, Delanty N, Brennan P, et al. Herpes simplex virus encephalitis involving the right thalamus. *BMJ Case Rep* 2013;2013.
109. Rigamonti A, Lauria G, Mantero V, et al. A case of late herpes simplex encephalitis relapse. *J Clin Virol* 2013;58(1):269-270.
110. Shaikh AG, Termsarasab P, Riley DE, et al. The floccular syndrome in herpes simplex type 1 encephalitis. *J Neurol Sci* 2013;325(1-2):154-155.
111. Tandon AS. Choreoathetosis in herpes simplex encephalitis relapse with bilateral thalamic gliotic lesions on magnetic resonance imaging. *Neurol India* 2012;60(5):526-527.
112. Sokolov AA, Reincke M. Herpes simplex encephalitis affecting the entire limbic system. *Mayo Clin Proc* 2012;87(9):e69.
113. Kim SJ, Kang SW, Joo EY. An unusual case of herpes simplex viral encephalitis following acute retinal necrosis after administration of a systemic steroid. *J Epilepsy Res* 2012;2(1):21-24.
114. Adler AC, Kadimi S, Apaloo C, et al. Herpes simplex encephalitis with two false-negative cerebrospinal fluid PCR tests and review of negative PCR results in the clinical setting. *Case Rep Neurol* 2011;3(2):172-178.
115. Raper DM, Wong A, McCormick PC, et al. Herpes simplex encephalitis following spinal ependymoma resection: case report and literature review. *J Neurooncol* 2011;103(3):771-776.
116. Yochim BP, Kane KD, Horning S, et al. Malingering or expected deficits? A case of herpes simplex encephalitis. *Neurocase* 2010;16(5):451-460.
117. Yen CF, Patel MS, Chu P, et al. Case report: herpes simplex encephalitis in cancer patients. *Biosci Trends* 2009;3(1):38-40.
118. Markoula S, Giannopoulos S, Pelidou SH, et al. MRI deterioration in herpes simplex encephalitis despite clinical recovery. *Neurologist* 2009;15(4):223-226.
119. Sellner J, Buonomano R, Nedeltchev K, et al. A case of maternal herpes simplex virus encephalitis during late pregnancy. *Nat Clin Pract Neurol* 2009;5(1):51-56.
120. Akyldz BN, Gumus H, Kumandas S, et al. Diffusion-weighted magnetic resonance is better than polymerase chain reaction for early diagnosis of herpes simplex encephalitis: a case report. *Pediatr Emerg Care* 2008;24(6):377-379.
121. Sobolewski P, Sledzinska M, Hatalska-Zerebiec R, et al. [Favourable course of herpes simplex encephalitis in the 37-year-old woman in 26th weeks of pregnancy]. *Przeegl Epidemiol* 2008;62 Suppl 1:109-111.

122. Gumus H, Kumandas S, Per H, et al. Unusual presentation of herpes simplex virus encephalitis: bilateral thalamic involvement and normal imaging of early stage of the disease. *Am J Emerg Med* 2007;25(1):87-89.
123. Kubota T, Ito M, Maruyama K, et al. Serial diffusion-weighted imaging of neonatal herpes encephalitis: a case report. *Brain Dev* 2007;29(3):171-173.
124. Hirai R, Ayabe M, Shoji H, et al. Herpes simplex encephalitis presenting with bilateral hippocampal lesions on magnetic resonance imaging, simultaneously complicated by small cell lung carcinoma. *Intern Med* 2005;44(9):1006-1008.
125. Heiner L, Demaerel P. Diffusion-weighted MR imaging findings in a patient with herpes simplex encephalitis. *Eur J Radiol* 2003;45(3):195-198.
126. Allmendinger AM, Spektor V, Destian S. CT and MR imaging of Susac syndrome in a young male presenting with acute disorientation. *Clin Imaging* 2010;34(2):138-142.
127. White ML, Zhang Y, Smoker WR. Evolution of lesions in Susac syndrome at serial MR imaging with diffusion-weighted imaging and apparent diffusion coefficient values. *AJNR Am J Neuroradiol* 2004;25(5):706-713.
128. Snyers B, Boschi A, De Potter P, et al. Susac syndrome in four male patients. *Retina* 2006;26(9):1049-1055.
129. Maillart E, Deschamps R, Moulignier A, et al. [Susac syndrome: study of five cases]. *Rev Neurol (Paris)* 2009;165(6-7):575-582.
130. Mateen FJ, Zubkov AY, Muralidharan R, et al. Susac syndrome: clinical characteristics and treatment in 29 new cases. *Eur J Neurol* 2012;19(6):800-811.
131. Xu MS, Tan CB, Umapathi T, et al. Susac syndrome: serial diffusion-weighted MR imaging. *Magn Reson Imaging* 2004;22(9):1295-1298.
132. Chawla A, Sathasivam S, Nayar R, et al. Susac syndrome in a patient with hepatitis C. *J Neuroophthalmol* 2007;27(1):55-56.
133. Le Moigne F, Lamboley JL, Vitry T, et al. [Susac syndrome, retinocochleocerebral microangiopathy: contribution of MRI]. *J Neuroradiol* 2009;36(5):285-289.
134. Joe SG, Kim JG, Kwon SU, et al. Recurrent bilateral branch retinal artery occlusion with hearing loss and encephalopathy: the first case report of Susac syndrome in Korea. *J Korean Med Sci* 2011;26(11):1518-1521.
135. Robles-Cedeno R, Ramio-Torrenta L, Laguillo G, et al. Long-term clinical and radiological evolution in one case of Susac's syndrome. *Neurol Sci* 2012;33(6):1407-1410.
136. Randakeviciene G, Gleizniene R, Nylander R. Susac's Syndrome: A Case Presentation and Radiological Approach to this Rare Autoimmune Endotheliopathy. *Medicina (Kaunas)* 2013;49(1):15-17.
137. Allmendinger AM, Viswanadhan N, Klufas RA, et al. Diffuse cauda equina enhancement in a middle aged male with Susac syndrome and symptomatic cauda equina syndrome. *J Neurol Sci* 2013;333(1-2):25-28.
138. Cho HJ, Kim CG, Cho SW, et al. A case of Susac syndrome. *Korean J Ophthalmol* 2013;27(5):381-383.
139. Allmendinger AM, Mallery RM, Magro CM, et al. Cauda equina involvement in Susac's syndrome. *J Neurol Sci* 2014;337(1-2):91-96.
140. Antulov R, Holjar Erlic I, Perkovic O, et al. Susac's syndrome during pregnancy - the first Croatian case. *J Neurol Sci* 2014;341(1-2):162-164.

141. Hua le H, Donlon SL, Okuda DT. A case of Susac syndrome with cervical spinal cord involvement on MRI. *J Neurol Sci* 2014;337(1-2):228-231.
142. Dielman C, Laureys G, Meurs A, et al. Susac syndrome: a case report and PET imaging findings. *Acta Neurol Belg* 2009;109(3):226-230.
143. Hayashi R, Hanyu N, Kuwabara T, et al. Serial computed tomographic and electroencephalographic studies in Creutzfeldt-Jakob disease. *Acta Neurol Scand* 1992;85(3):161-165.
144. Garcia Santos JM, Lopez Corbalan JA, Martinez-Lage JF, et al. CT and MRI in iatrogenic and sporadic Creutzfeldt-Jakob disease: as far as imaging perceives. *Neuroradiology* 1996;38(3):226-231.
145. Kovanen J, Erkinjuntti T, Iivanainen M, et al. Cerebral MR and CT imaging in Creutzfeldt-Jakob disease. *J Comput Assist Tomogr* 1985;9(1):125-128.
146. Schroter A, Zerr I, Henkel K, et al. Magnetic resonance imaging in the clinical diagnosis of Creutzfeldt-Jakob disease. *Arch Neurol* 2000;57(12):1751-1757.
147. Shiga Y, Miyazawa K, Sato S, et al. Diffusion-weighted MRI abnormalities as an early diagnostic marker for Creutzfeldt-Jakob disease. *Neurology* 2004;63(3):443-449.
148. Vitali P, Maccagnano E, Caverzasi E, et al. Diffusion-weighted MRI hyperintensity patterns differentiate CJD from other rapid dementias. *Neurology* 2011;76(20):1711-1719.
149. Collins SJ, Sanchez-Juan P, Masters CL, et al. Determinants of diagnostic investigation sensitivities across the clinical spectrum of sporadic Creutzfeldt-Jakob disease. *Brain* 2006;129(Pt 9):2278-2287.
150. Collie DA, Summers DM, Sellar RJ, et al. Diagnosing variant Creutzfeldt-Jakob disease with the pulvinar sign: MR imaging findings in 86 neuropathologically confirmed cases. *AJNR Am J Neuroradiol* 2003;24(8):1560-1569.
151. Xing XW, Zhang JT, Zhu F, et al. Comparison of diffusion-weighted MRI with 18F-fluorodeoxyglucose-positron emission tomography/CT and electroencephalography in sporadic Creutzfeldt-Jakob disease. *J Clin Neurosci* 2012;19(10):1354-1357.
152. Fujita K, Harada M, Sasaki M, et al. Multicentre multiobserver study of diffusion-weighted and fluid-attenuated inversion recovery MRI for the diagnosis of sporadic Creutzfeldt-Jakob disease: a reliability and agreement study. *BMJ Open* 2012;2(1):e000649.
153. Meissner B, Kallenberg K, Sanchez-Juan P, et al. MRI lesion profiles in sporadic Creutzfeldt-Jakob disease. *Neurology* 2009;72(23):1994-2001.
154. Manners DN, Parchi P, Tonon C, et al. Pathologic correlates of diffusion MRI changes in Creutzfeldt-Jakob disease. *Neurology* 2009;72(16):1425-1431.
155. Yi SH, Park KC, Yoon SS, et al. Relationship between clinical course and Diffusion-weighted MRI findings in sporadic Creutzfeldt-Jakob Disease. *Neurol Sci* 2008;29(4):251-255.
156. Krasnianski A, Kallenberg K, Collie DA, et al. MRI in the classical MM1 and the atypical MV2 subtypes of sporadic CJD: an inter-observer agreement study. *Eur J Neurol* 2008;15(8):762-771.
157. Satoh K, Shirabe S, Tsujino A, et al. Total tau protein in cerebrospinal fluid and diffusion-weighted MRI as an early diagnostic marker for Creutzfeldt-Jakob disease. *Dement Geriatr Cogn Disord* 2007;24(3):207-212.
158. Tschampa HJ, Kallenberg K, Urbach H, et al. MRI in the diagnosis of sporadic Creutzfeldt-Jakob disease: a study on inter-observer agreement. *Brain* 2005;128(Pt 9):2026-2033.
159. Nougaret S, Brunel H, Bourbotte G, et al. [Diffusion-weighted MRI in sporadic Creutzfeldt-Jakob disease]. *J Neuroradiol* 2007;34(4):260-266.

160. Cambier DM, Kantarci K, Worrell GA, et al. Lateralized and focal clinical, EEG, and FLAIR MRI abnormalities in Creutzfeldt-Jakob disease. *Clin Neurophysiol* 2003;114(9):1724-1728.
161. Uemura A, O'Uchi T, Sakamoto T, et al. High signal of the striatum in sporadic Creutzfeldt-Jakob disease: sequential change on T2-weighted MRI. *Neuroradiology* 2002;44(4):314-318.
162. Urbach H, Paus S, Tschampa HJ, et al. [Creutzfeldt-Jakob disease: value of MRI]. *Rofo* 2001;173(6):509-514.
163. Nitrini R, Mendonca RA, Huang N, et al. Diffusion-weighted MRI in two cases of familial Creutzfeldt--Jakob disease. *J Neurol Sci* 2001;184(2):163-167.
164. Coulthard A, Hall K, English PT, et al. Quantitative analysis of MRI signal intensity in new variant Creutzfeldt-Jakob disease. *Br J Radiol* 1999;72(860):742-748.
165. Urbach H, Klisch J, Wolf HK, et al. MRI in sporadic Creutzfeldt-Jakob disease: correlation with clinical and neuropathological data. *Neuroradiology* 1998;40(2):65-70.
166. Liou HH, Chiu HC, Liu HM. Abnormal enhancement of the left putamen on brain MRI in a case of proven Creutzfeldt-Jakob disease. *Eur Neurol* 1996;36(2):107-108.
167. Tartaro A, Fulgente T, Delli Pizzi C, et al. MRI alterations as an early finding in Creutzfeld-Jakob disease. *Eur J Radiol* 1993;17(3):155-158.
168. Onofrj M, Fulgente T, Gambi D, et al. Early MRI findings in Creutzfeldt-Jakob disease. *J Neurol* 1993;240(7):423-426.
169. Di Rocco A, Molinari S, Stollman AL, et al. MRI abnormalities in Creutzfeldt-Jakob disease. *Neuroradiology* 1993;35(8):584-585.
170. Katsube M, Shiota Y, Harada T, et al. [A case of MM1+2 Creutzfeldt-Jakob disease with a longitudinal study of EEG and MRI]. *Rinsho Byori* 2013;61(11):995-1000.
171. Moisset X, Vitello N, Cornut-Chauvinc C, et al. [Unilateral Creutzfeld-Jakob disease: report of a probable case on electroclinical, MRI and biological criteria]. *Rev Neurol (Paris)* 2013;169(2):162-165.
172. Kono S, Manabe Y, Fujii D, et al. Serial diffusion-weighted MRI and SPECT findings in a Creutzfeldt-Jakob disease patient with V180I mutation. *J Neurol Sci* 2011;301(1-2):100-103.
173. Yung B, Moeller JJ, Bitar M, et al. Teaching NeuroImages: hemispheric-onset Creutzfeldt-Jakob disease with concordant MRI and EEG findings. *Neurology* 2010;75(16):e66.
174. Mourand I, Grandiere-Perez L, Joyes B, et al. Lateralized clinical and diffusion-weighted MRI abnormalities in a probable case of sporadic Creutzfeldt-Jakob disease. *Acta Neurol Belg* 2010;110(2):193-195.
175. Tian HJ, Zhang JT, Lang SY, et al. MRI sequence findings in sporadic Creutzfeldt-Jakob disease. *J Clin Neurosci* 2010;17(11):1378-1380.
176. Prasad S, Lee EB, Woo JH, et al. Photo essay. MRI and positron emission tomography findings in Heidenhain variant Creutzfeldt-Jakob disease. *J Neuroophthalmol* 2010;30(3):260-262.
177. Satoh K, Nakaoke R, Nishiura Y, et al. Early detection of sporadic CJD by diffusion-weighted MRI before the onset of symptoms. *J Neurol Neurosurg Psychiatry* 2011;82(8):942-943.
178. Geschwind MD, Potter CA, Sattavat M, et al. Correlating DWI MRI with pathologic and other features of Jakob-Creutzfeldt disease. *Alzheimer Dis Assoc Disord* 2009;23(1):82-87.
179. Praveen KS, Sinha S, Chandrasekhar HS, et al. Sporadic onset Creutzfeldt-Jacob disease: interesting MRI observations. *Neurol India* 2006;54(4):418-420.
180. Nitrini R, Areza-Fegyveres R, Martins VR, et al. [Asymmetric cortical high signal on diffusion weighted-MRI in a case of Creutzfeldt-Jakob disease]. *Arq Neuropsiquiatr* 2005;63(2B):519-522.

181. Pauri F, Amabile G, Fattapposta F, et al. Sporadic Creutzfeldt-Jakob disease without dementia at onset: clinical features, laboratory tests and sequential diffusion MRI (in an autopsy-proven case). *Neurol Sci* 2004;25(4):234-237.
182. Donahue JE, Hanna PA, Hariharan S. Autopsy-proven Creutzfeldt-Jakob disease in a patient with a negative 14-3-3 assay and nonspecific EEG and MRI. *Neurol Sci* 2004;24(6):411-413.
183. Bocquet P, De Stampa M, Foucher C, et al. [Sporadic Creutzfeldt-Jakob disease and isolated dementia. Contribution of brain MRI]. *Ann Med Interne (Paris)* 2002;153(1):62-67.
184. Tribl GG, Strasser G, Zeithofer J, et al. Sequential MRI in a case of Creutzfeldt-Jakob disease. *Neuroradiology* 2002;44(3):223-226.
185. Konagaya M, Sakai M, Asakura K, et al. [T2-weighted MRI and pathological findings in the cerebral hemisphere of panencephalitic Creutzfeldt-Jakob disease]. *No To Shinkei* 2001;53(4):398-399.
186. Matoba M, Tonami H, Miyaji H, et al. Creutzfeldt-Jakob disease: serial changes on diffusion-weighted MRI. *J Comput Assist Tomogr* 2001;25(2):274-277.
187. Oppenheim C, Brandel JP, Hauw JJ, et al. MRI and the second French case of vCJD. *Lancet* 2000;356(9225):253-254.
188. Vrancken AF, Frijns CJ, Ramos LM. FLAIR MRI in sporadic Creutzfeldt-Jakob disease. *Neurology* 2000;55(1):147-148.
189. Saito T, Isozumi K, Komatsumoto S, et al. [A case of codon 232 mutation-induced Creutzfeldt-Jakob disease visualized by the MRI-FLAIR images with atypical clinical symptoms]. *Rinsho Shinkeigaku* 2000;40(1):51-54.
190. Samman I, Schulz-Schaeffer WJ, Wohrle JC, et al. Clinical range and MRI in Creutzfeldt-Jakob disease with heterozygosity at codon 129 and prion protein type 2. *J Neurol Neurosurg Psychiatry* 1999;67(5):678-681.
191. Nagaoka U, Kurita K, Hosoya T, et al. [Diffusion images on brain MRI in Creutzfeldt-Jakob disease]. *Rinsho Shinkeigaku* 1999;39(4):468-470.
192. Hirose Y, Mokuno K, Abe Y, et al. [A case of clinically diagnosed Creutzfeldt-Jakob disease with serial MRI diffusion weighted images]. *Rinsho Shinkeigaku* 1998;38(8):779-782.
193. Satoh A, Goto H, Satoh H, et al. A case of Creutzfeldt-Jakob disease with a point mutation at codon 232: correlation of MRI and neurologic findings. *Neurology* 1997;49(5):1469-1470.
194. Kobayashi S, Ohuchi T, Maki T. [A case of probable Creutzfeldt-Jakob disease with a point mutation of prion protein gene codon 180 and atypical MRI findings]. *Rinsho Shinkeigaku* 1997;37(8):671-674.
195. Ishida S, Sugino M, Koizumi N, et al. Serial MRI in early Creutzfeldt-Jacob disease with a point mutation of prion protein at codon 180. *Neuroradiology* 1995;37(7):531-534.
196. Yoon SS, Chan S, Chin S, et al. MRI of Creutzfeldt-Jakob disease: asymmetric high signal intensity of the basal ganglia. *Neurology* 1995;45(10):1932-1933.
197. Gertz HJ, Henkes H, Cervos-Navarro J. Creutzfeldt-Jakob disease: correlation of MRI and neuropathologic findings. *Neurology* 1988;38(9):1481-1482.
198. Sarac H, Hajnsek S, Basic S, et al. Magnetic resonance spectroscopy and measurement of tau epitopes of autopsy proven sporadic Creutzfeldt-Jakob disease in a patient with non-specific initial EEG, MRI and negative 14-3-3 immunoblot. *Coll Antropol* 2008;32 Suppl 1:199-204.